dehydroepiandrosterone has been researched along with Menopause in 261 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women." | 9.51 | Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 9.27 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 9.22 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 9.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "Various plasma hormones were measured in 13 pre- and 20 post-menopausal women with advanced breast cancer before and for 12 months after ovarian irradiation or during continuous administration of tamoxifen at a dose of 10 mg twice a day, respectively; some patients received additional prednisolone at a dose of 5 mg twice a day." | 9.05 | Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer. ( Blackburn, AM; Bulbrook, RD; Hoare, SA; Kwa, HG; Rubens, RD; Thomas, BS; Wang, DY, 1984) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 9.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 9.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "Prolactin levels were evaluated over a 2-year period in three groups of postmenopausal women: group A consisted of 35 untreated women distributed according to time since the menopause; group B consisted of 17 women on a combined estrogen/androgen preparation (Gynodian depot) intramuscularly at monthly intervals; and group C consisted of 12 women on 100 units of salmon calcitonin intranasally on alternate days and 1500 mg calcium daily." | 7.69 | Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. ( Balint-Perić, LA; Prelević, GM, 1997) |
| "The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45-65 years) with rheumatoid arthritis (RA) and related to assessments of bone mineral density at the spine and proximal femur." | 7.68 | Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. ( Hall, GM; Perry, LA; Spector, TD, 1993) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 7.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "The possibility that medroxyprogesterone acetate (MPA) is clinically effective at least in part by its suppression of adrenal steroidogenesis and a resultant reduction of circulating oestrogen levels was investigated in 49 postmenopausal patients with advanced breast cancer." | 7.67 | The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Lal, A; Smith, IE, 1987) |
| " Tamoxifen, an anti-estrogen, is used in the treatment of women with breast cancer in whom metastatic disease has been demonstrated." | 7.67 | Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1985) |
| "Plasma concentrations of dehydroepiandrosterone (DHA), DHA-sulphate (DHAS) and 7 alpha hydroxy-DHA (7 alpha OHDHA) were measured and compared with tumor estrogen receptor (ER) status in 33 postmenopausal patients with breast cancer." | 7.67 | Estrogen receptor status, adrenal androgens and 7 alpha-hydroxydehydroepiandrosterone in breast cancer patients. ( Couch, RA; Holdaway, IM; Kay, RG; Mason, BH; Skinner, SJ, 1984) |
| "Peripheral serum levels of cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHA-S), oestradiol-17 beta and total oestrone were measured in 17 postmenopausal breast cancer patients and on age-matched healthy controls." | 7.66 | Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients. ( Carlström, K; Sköldefors, H; Theve, NO; Wallgren, A; Wilking, N, 1982) |
| "Cortisol and dehydroepiandrosterone sulphate (DHAS) were measured in saliva from postmenopausal women with primary breast cancer and a control group of comparable age." | 7.66 | Salivary cortisol and dehydroepiandrosterone sulphate levels in postmenopausal women with primary breast cancer. ( Blamey, RW; Campbell, FC; Griffiths, K; Holliday, HW; Read, GF; Wilson, DW, 1983) |
| "The 24-hr mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate were measured in 11 women with primary operable breast cancer, ages 31 to 78 years, and in 37 normal women, ages 21 to 75 years." | 7.66 | Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. ( Fukushima, DK; Levin, J; Markham, M; Rosenfeld, RS; Strain, GW; Zumoff, B, 1981) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 7.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Intravaginal dehydroepiandrosterone (DHEA) is a locally metabolised estrogen and androgen precursor, licensed in 2018 in the EU for moderate to severe vulvovaginal atrophy in postmenopausal women." | 5.51 | Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? ( Bruce, D; Holloway, D; Kearley-Shiers, K, 2022) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 5.27 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; BSc, AB; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2018) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 5.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| "The aim of this study is to confirm the local beneficial effects of intravaginal dehydroepiandrosterone (DHEA, Prasterone) on moderate to severe dyspareunia or pain at sexual activity, the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM)." | 5.22 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. ( Archer, DF; Balser, J; Beauregard, A; Côté, I; Frenette, L; Koltun, W; Labrie, F; Lavoie, L; Martel, C; Montesino, M; Moyneur, É; Parent, J; Portman, D; Vachon, A; Vaillancourt, M; Young, D, 2016) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 5.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 5.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 5.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Various plasma hormones were measured in 13 pre- and 20 post-menopausal women with advanced breast cancer before and for 12 months after ovarian irradiation or during continuous administration of tamoxifen at a dose of 10 mg twice a day, respectively; some patients received additional prednisolone at a dose of 5 mg twice a day." | 5.05 | Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer. ( Blackburn, AM; Bulbrook, RD; Hoare, SA; Kwa, HG; Rubens, RD; Thomas, BS; Wang, DY, 1984) |
| " estradiol, dehydroepiandrosterone [DHEA], progesterone) that causes menopause commonly affects a woman's general health and produces bothersome physical changes that may interfere with normal sexual and genitourinary functioning." | 5.01 | Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. ( Goldstein, SR; Kagan, R; Portman, DJ, 2019) |
| "Menopause has been chosen by evolution as the convergence of three factors, namely cessation of ovarian function (reproduction and estrogen secretion), high circulating dehydroepiandrosterone (DHEA), and intracrine enzymes able to convert DHEA into active sex steroids in peripheral tissues." | 4.89 | DHEA and intracrinology at menopause, a positive choice for evolution of the human species. ( Labrie, C; Labrie, F, 2013) |
| " Three hormonal systems show decreasing circulating hormone concentrations during normal aging: (i) estrogen (in menopause) and testosterone (in andropause), (ii) dehydroepiandrosterone and its sulphate (in adrenopause), and (iii) the growth hormone/insulin-like growth factor I axis (in somatopause)." | 4.79 | The endocrinology of aging. ( Lamberts, SW; van den Beld, AW; van der Lely, AJ, 1997) |
| "Vaginal dehydroepiandrosterone, hypothesized to enhance local production of both androgen and estrogen, is effective for the management of dyspareunia in menopause." | 3.88 | The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. ( Archer, DF; Bachmann, G; Davis, SR; Goldstein, AT; Goldstein, I; Kellogg-Spadt, S; Kim, NN; Lowenstein, L; Nappi, RE; Pinkerton, JV; Simon, JA; Stuenkel, CA; Traish, AM; Vignozzi, L, 2018) |
| " Dehydroepiandrosterone (DHEA) protects against cardiovascular diseases, but results among previous studies have been inconsistent." | 3.83 | Dehydroepiandrosterone-sulfate is associated with cardiovascular reactivity to stress in women. ( Hirokawa, K; Imano, H; Iso, H; Kajiura, M; Kitamura, A; Kiyama, M; Nagayoshi, M; Ohira, T; Okada, T, 2016) |
| "A major achievement from 500 million years of evolution is the establishment of a high secretion rate of dehydroepiandrosterone (DHEA) by the human adrenal glands coupled with the indroduction of menopause which stops secretion of estrogens by the ovary." | 3.76 | DHEA, important source of sex steroids in men and even more in women. ( Labrie, F, 2010) |
| " The aim of the present study was to assess serum allopregnanolone concentrations according to gender, menstrual cycle, age, and menopause in normal men and women; serum progesterone (P) and dehydroepiandrosterone (DHEA) levels were evaluated in the same specimens." | 3.70 | Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. ( Bernardi, F; Casarosa, E; Genazzani, AR; Luisi, M; Luisi, S; Nappi, RE; Palumbo, M; Petraglia, F; Purdy, RH; Salvestroni, C; Tonetti, A, 1998) |
| "The relationships between urinary 11-desoxy-17-oxo steroids (11-DOS), the ratio of 11-DOS to urinary 17-hydroxycorticosteroids (urinary discriminant ratio), plasma levels of the adrenal androgens dehydroepiandrosterone (DHA), DHA sulphate (DHAS), and 7 alpha-hydroxy DHA (7 alpha DHA), and tumour oestrogen receptor (ER) and progesterone receptor (PR) status were examined in pre, peri-, and postmenopausal women with breast cancer." | 3.69 | The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival. ( Holdaway, IM; Kay, RG; Mason, BH; Skinner, SJ, 1994) |
| "Tamoxifen is considered an antiestrogen against breast cancer, yet it has known estrogenic side effects." | 3.69 | Changes in serum estrogen levels in women during tamoxifen therapy. ( Fletcher, WS; Lum, SS; Pommier, RF; Woltering, EA, 1997) |
| "Prolactin levels were evaluated over a 2-year period in three groups of postmenopausal women: group A consisted of 35 untreated women distributed according to time since the menopause; group B consisted of 17 women on a combined estrogen/androgen preparation (Gynodian depot) intramuscularly at monthly intervals; and group C consisted of 12 women on 100 units of salmon calcitonin intranasally on alternate days and 1500 mg calcium daily." | 3.69 | Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. ( Balint-Perić, LA; Prelević, GM, 1997) |
| "To investigate the effect of low doses of 2 different glucocorticoids on bone mass, sex hormone status and bone metabolic indices, a study was undertaken in 16 postmenopausal women with rheumatoid arthritis (RA) receiving < 15 mg/day of deflazacort and in 16 patients with RA matched for age, years postmenopause and disease duration, receiving < 10 mg/day of prednisone." | 3.68 | Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. ( Caporali, R; Caprotti, M; Caprotti, P; Montecucco, C; Notario, A, 1992) |
| "The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45-65 years) with rheumatoid arthritis (RA) and related to assessments of bone mineral density at the spine and proximal femur." | 3.68 | Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. ( Hall, GM; Perry, LA; Spector, TD, 1993) |
| "Circulating preoperative levels of DHEA-S, androstenedione and SHBG were measured in 40 premenopausal and 49 postmenopausal breast cancer patients, and in 30 and 15 age-matched healthy controls, respectively." | 3.68 | Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients. ( Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Suthar, TP; Trivedi, SN; Vora, HH, 1992) |
| "Dehydroepiandrosterone sulfate (DHEAS), testosterone, androstenedione, 17-beta estradiol and sex hormone binding globulin have been assayed in 50 HLA-identical postmenopausal rheumatoid arthritis (RA) discordant sibling pairs." | 3.68 | Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs. ( Deighton, CM; Walker, DJ; Watson, MJ, 1992) |
| "Dehydroepiandrosterone (DHEA) has an anti-obesity effect in rodents and reduces body fat in normal men." | 3.68 | Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index. ( Cignarelli, M; Cospite, MR; De Pergola, G; Garruti, G; Giagulli, VA; Giorgino, F; Giorgino, R, 1991) |
| "We investigated the role of androgens in premenopausal breast cancer by comparing serum testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone sulfate, progesterone, sex-hormone-binding globulin-binding capacity, and urinary testosterone and androstanediol in 63 women with breast adenocarcinoma and 70 healthy controls of similar age." | 3.67 | Androgens and breast cancer in premenopausal women. ( Berrino, F; Cavalleri, A; Di Pietro, S; Fariselli, G; Pisani, P; Recchione, C; Secreto, G; Toniolo, P; Totis, A, 1989) |
| " Tamoxifen, an anti-estrogen, is used in the treatment of women with breast cancer in whom metastatic disease has been demonstrated." | 3.67 | Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1985) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 3.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "The possibility that medroxyprogesterone acetate (MPA) is clinically effective at least in part by its suppression of adrenal steroidogenesis and a resultant reduction of circulating oestrogen levels was investigated in 49 postmenopausal patients with advanced breast cancer." | 3.67 | The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients. ( Dowsett, M; Jeffcoate, SL; Lal, A; Smith, IE, 1987) |
| "Plasma concentrations of dehydroepiandrosterone (DHA), DHA-sulphate (DHAS) and 7 alpha hydroxy-DHA (7 alpha OHDHA) were measured and compared with tumor estrogen receptor (ER) status in 33 postmenopausal patients with breast cancer." | 3.67 | Estrogen receptor status, adrenal androgens and 7 alpha-hydroxydehydroepiandrosterone in breast cancer patients. ( Couch, RA; Holdaway, IM; Kay, RG; Mason, BH; Skinner, SJ, 1984) |
| " This loss, combined with the low plasma concentrations of androstenedione, dehydroepiandrosterone, and testosterone (and low concentrations of oestrone of adrenal origin), indicates that adrenal androgens may be essential for the maintenance of bone mass in postmenopausal women with Addison's disease." | 3.67 | Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. ( Crabbé, J; Devogelaer, JP; Nagant de Deuxchaisnes, C, 1987) |
| "The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer." | 3.67 | Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. ( Cantwell, BM; Dowsett, M; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "Cortisol and dehydroepiandrosterone sulphate (DHAS) were measured in saliva from postmenopausal women with primary breast cancer and a control group of comparable age." | 3.66 | Salivary cortisol and dehydroepiandrosterone sulphate levels in postmenopausal women with primary breast cancer. ( Blamey, RW; Campbell, FC; Griffiths, K; Holliday, HW; Read, GF; Wilson, DW, 1983) |
| "The 24-hr mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate were measured in 11 women with primary operable breast cancer, ages 31 to 78 years, and in 37 normal women, ages 21 to 75 years." | 3.66 | Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. ( Fukushima, DK; Levin, J; Markham, M; Rosenfeld, RS; Strain, GW; Zumoff, B, 1981) |
| "Peripheral serum levels of cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulphate (DHA-S), oestradiol-17 beta and total oestrone were measured in 17 postmenopausal breast cancer patients and on age-matched healthy controls." | 3.66 | Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients. ( Carlström, K; Sköldefors, H; Theve, NO; Wallgren, A; Wilking, N, 1982) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 3.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "Clinical and metabolic effects of depot-injections of estradiol valerianate-dehydroepiandrosterone enanthate at a 1:50 ratio (Gynodian-depot) in the treatment of severe clinical manifestations of the vegetoneurotic syndrome were evaluated in menopuasal patients after hysterectomy for uterine myoma." | 3.66 | Clinical and metabolic effects of Gynodian-depot in vegetoneurotic disorders following removal of uterine myoma in menopausal patients. ( Talina, IS; Uvarova, EV; Vikhliaeva, EM, 1983) |
| "Measurement of the excretion of total 17-ketosteroids, androsterone, etiocholanolone, and dehydroepiandrosterone demonstrate in contrast to the well known age dependency of normal women in cases of both mastopathia and breast cancer the following results: 1." | 3.65 | Investigation of 17-ketosteriod excretion in mastopathia and premenopausal breast cancer. ( Eckhardt, S; Hindy, I; Prajda, N; Sellei, C; Tapolcsányi, L, 1975) |
| " Our review determined that amongst published RCTs, no studies have aimed to assess for breast cancer recurrence; however among the studies observing for serious adverse effects of vaginal estrogen preparations, none have reported an increased incidence." | 3.01 | A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors. ( Hussain, I; Talaulikar, VS, 2023) |
| "To date, studies are limited by including small numbers of women, the difficulty of dosing androgens, and their cyclical variations." | 2.82 | Revisiting the physiological role of androgens in women. ( Anastasiadou, E; Lenzi, A; Rosato, E; Sciarra, F; Venneri, MA, 2022) |
| "Insulin sensitivity was estimated using the insulin sensitivity index and the quantitative insulin sensitivity check index, whereas insulin resistance was estimated using the homeostatic model for insulin resistance." | 2.79 | Association between circulating endogenous androgens and insulin sensitivity changes with exercise training in midlife women. ( Campbell, C; Gaikwad, NW; Gustafson, MB; Keim, NL; Krishnan, S, 2014) |
| " Ospemifene therapy was however superior to laser and vaginal estrogen therapies in ameliorating sexual function, however, it presents a high risk of developing adverse events and endometrial hyperplasia." | 2.72 | Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. ( Chang, Y; Duan, H; Li, B; Wang, S, 2021) |
| "Patients with breast cancer receiving antiestrogen therapy, specifically aromatase inhibitors, often suffer from vaginal dryness, itching, irritation, dyspareunia, and dysuria, collectively known as genitourinary syndrome of menopause (GSM)." | 2.61 | Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. ( Abraham, J; Kruse, ML; Sussman, TA; Thacker, HL, 2019) |
| "In some breast cancer cell lines in a low oestrogen milieu DHEA has an oestradiol-like effect, stimulating tumour growth, whereas in oestradiol abundance DHEA antagonises the growth-stimulating effect of oestradiol." | 2.39 | Physiological importance of dehydroepiandrosterone. ( Ebeling, P; Koivisto, VA, 1994) |
| "The low incidence of breast cancer in Japan disappears within 2 generations in migrant Japanese in the USA." | 2.38 | Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5-steroids in tumorigenesis. ( Adams, JB, 1992) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| " Prasterone seems a safe and effective option to treat GSM in BCS receiving AIs." | 1.72 | Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. ( Alonso, I; Anglès-Acedo, S; Castelo-Branco, C; Castrejon, N; Cebrecos, I; Gómez, S; Matas, I; Mension, E; Ribera, L; Tortajada, M, 2022) |
| "Intrinsic skin aging is determined primarily by genetic factors and hormonal status." | 1.32 | [Intrinsic skin aging. A critical appraisal of the role of hormones]. ( Zouboulis, ChC, 2003) |
| "Dehydroepiandrosterone (DHEA) has an antiobesity effect in rodents, and elevated endogenous levels of its sulfate ester (DHEAS) are associated with reductions in risk for cardiovascular disease (CVD) in men." | 1.29 | Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. ( Boyden, TW; Going, SB; Lohman, TG; Pamenter, RW; Williams, DP, 1993) |
| "Although the perimenopause is associated with increases in baseline and stimulated gonadotropin levels similar to those seen after the menopause, significantly increased baseline luteinizing hormone bioactivity and the bioactivity/immunoactivity ratio are seen only after the menopause." | 1.29 | Basal and stimulated gonadotropin levels in the perimenopause. ( Baron, DA; Gindoff, PR; Rubinow, DR; Schmidt, PJ, 1996) |
| "The concentration of Adione in breast cancer tissue is much lower than the reported Km of the aromatase system for Adione." | 1.28 | Tissue androgens and the endocrine autonomy of breast cancer. ( Blankenstein, MA; Daroszewski, J; Donker, GH; Maitimu-Smeele, I; Milewicz, A; Thijssen, JH, 1992) |
| "Dehydroepiandrosterone was also measured in the 800 g fraction of 45 tumors and its concentration, which was some 10-fold higher than ADIOL and significantly correlated with that steroid, was again independent of menopausal status." | 1.28 | Estrogen receptor and C19-5-ene-steroid concentrations in the nuclear fraction from human breast carcinoma tissue. ( Adams, JB; Seymour-Munn, K, 1992) |
| "Prevention of postmenopausal osteoporosis is now possible with current therapy, if initiated soon after the menopause and continued for at least 10 years." | 1.28 | The relationship between sex steroids and bone mineral content in women soon after the menopause. ( Edwards, AC; McGarrigle, HH; Perry, LA; Spector, TD; Thompson, PW, 1991) |
| "Women with advanced ovarian cancer had lower DHEAS levels than those with local ovarian cancer." | 1.27 | Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. ( Heinonen, PK; Koivula, T; Pystynen, P, 1987) |
| " A dose-response relation was apparent for these hormones; mean plasma levels increased concomitantly with cigarette consumption." | 1.27 | Cigarette smoking and levels of adrenal androgens in postmenopausal women. ( Barrett-Connor, E; Khaw, KT; Tazuke, S, 1988) |
| " Prednisolone therapy in 22 patients (mean dosage 8 mg/day) was associated with reductions in estrone and testosterone levels; however, DHEAS and femoral BMD were also decreased in RA patients who were not receiving corticosteroids." | 1.27 | Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. ( Champion, GD; Eisman, JA; Pocock, NA; Sambrook, PN, 1988) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 1.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| "The severity of the osteoporosis is directly related to the severity of the calcium malabsorption." | 1.27 | The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women. ( Bridges, A; Deam, S; Horowitz, M; Morris, HA; Need, AG; Nordin, BE; Philcox, JC; Robertson, A; Seamark, RF, 1985) |
| " It is concluded that the effects of estrogens on the endocrine system in peri- and postmenopausal women are influenced by chemical structure, dosage and mode of administration of the estrogen as well as by the endogenous hormone profile." | 1.26 | Treatment with oral estrone sulphate in the female climacteric. II. Hormonal aspects. ( Carlström, K; Lagrelius, A; Lunell, NO, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 141 (54.02) | 18.7374 |
| 1990's | 47 (18.01) | 18.2507 |
| 2000's | 23 (8.81) | 29.6817 |
| 2010's | 35 (13.41) | 24.3611 |
| 2020's | 15 (5.75) | 2.80 |
| Authors | Studies |
|---|---|
| Stute, P | 1 |
| Bertschy, S | 1 |
| Birkhaeuser, M | 1 |
| Bitzer, J | 1 |
| Ging, A | 1 |
| Raggi, A | 1 |
| Steimann, S | 1 |
| Stute, V | 1 |
| Mension, E | 1 |
| Alonso, I | 1 |
| Cebrecos, I | 1 |
| Castrejon, N | 1 |
| Tortajada, M | 1 |
| Matas, I | 1 |
| Gómez, S | 1 |
| Ribera, L | 1 |
| Anglès-Acedo, S | 1 |
| Castelo-Branco, C | 1 |
| Kearley-Shiers, K | 1 |
| Holloway, D | 1 |
| Bruce, D | 1 |
| Rosato, E | 1 |
| Sciarra, F | 2 |
| Anastasiadou, E | 1 |
| Lenzi, A | 1 |
| Venneri, MA | 1 |
| Salvatore, S | 3 |
| Benini, V | 3 |
| Ruffolo, AF | 3 |
| Degliuomini, RS | 3 |
| Redaelli, A | 3 |
| Casiraghi, A | 3 |
| Candiani, M | 3 |
| Cipriani, S | 2 |
| Maseroli, E | 2 |
| Ravelli, SA | 1 |
| Vignozzi, L | 3 |
| Casiano Evans, EA | 1 |
| Hobson, DTG | 1 |
| Aschkenazi, SO | 1 |
| Alas, AN | 1 |
| Balgobin, S | 1 |
| Balk, EM | 1 |
| Dieter, AA | 1 |
| Kanter, G | 1 |
| Orejuela, FJ | 1 |
| Sanses, TVD | 1 |
| Rahn, DD | 1 |
| Hussain, I | 1 |
| Talaulikar, VS | 1 |
| Gajarawala, SN | 1 |
| Wood, TA | 1 |
| Stanton, AP | 1 |
| Bıldırcın, FD | 1 |
| Özdeş, EK | 1 |
| Karlı, P | 1 |
| Özdemir, AZ | 1 |
| Kökçü, A | 1 |
| Holton, M | 1 |
| Thorne, C | 1 |
| Goldstein, AT | 2 |
| Lin, J | 1 |
| Tian, F | 1 |
| Chen, L | 1 |
| Wang, Y | 1 |
| Wang, M | 1 |
| Li, D | 1 |
| Wang, L | 1 |
| Zhu, J | 1 |
| Zhang, Y | 1 |
| Hans-Jürgen, G | 1 |
| Cellai, I | 1 |
| Di Stasi, V | 1 |
| Comeglio, P | 1 |
| Todisco, T | 1 |
| Corno, C | 1 |
| Filippi, S | 1 |
| Sorbi, F | 1 |
| Fambrini, M | 1 |
| Petraglia, F | 3 |
| Scavello, I | 1 |
| Rastrelli, G | 1 |
| Acciai, G | 1 |
| Villanelli, F | 1 |
| Danza, G | 1 |
| Sarchielli, E | 1 |
| Guarnieri, G | 1 |
| Morelli, A | 1 |
| Maggi, M | 1 |
| Smith, T | 1 |
| Sahni, S | 1 |
| Thacker, HL | 2 |
| Li, B | 1 |
| Duan, H | 1 |
| Chang, Y | 1 |
| Wang, S | 1 |
| Stensen, DB | 1 |
| Småbrekke, L | 1 |
| Olsen, K | 1 |
| Grimnes, G | 1 |
| Nielsen, CS | 1 |
| Sollid, JUE | 1 |
| Simonsen, GS | 1 |
| Almås, B | 1 |
| Furberg, AS | 1 |
| Urbanski, HF | 2 |
| Sorwell, KG | 2 |
| Prokai, L | 1 |
| Kohama, SG | 2 |
| Bachmann, G | 2 |
| Phillips, N | 1 |
| Shifren, JL | 2 |
| Simon, JA | 1 |
| Goldstein, I | 1 |
| Kim, NN | 1 |
| Davis, SR | 2 |
| Kellogg-Spadt, S | 1 |
| Lowenstein, L | 1 |
| Pinkerton, JV | 1 |
| Stuenkel, CA | 1 |
| Traish, AM | 1 |
| Archer, DF | 4 |
| Nappi, RE | 2 |
| Labrie, F | 13 |
| Koltun, W | 3 |
| Vachon, A | 2 |
| Young, D | 2 |
| Frenette, L | 2 |
| Portman, D | 2 |
| Montesino, M | 2 |
| Côté, I | 4 |
| Parent, J | 2 |
| Lavoie, L | 4 |
| BSc, AB | 1 |
| Martel, C | 6 |
| Vaillancourt, M | 2 |
| Balser, J | 4 |
| Moyneur, É | 2 |
| Portman, DJ | 2 |
| Goldstein, SR | 1 |
| Kagan, R | 1 |
| Giannini, A | 1 |
| Caretto, M | 1 |
| Genazzani, AR | 5 |
| Simoncini, T | 1 |
| Heo, YA | 1 |
| Sussman, TA | 1 |
| Kruse, ML | 1 |
| Abraham, J | 1 |
| Vegunta, S | 1 |
| Files, J | 1 |
| Kling, JM | 1 |
| Conley, AJ | 1 |
| Stanczyk, FZ | 1 |
| Morrison, JH | 1 |
| Borowicz, P | 1 |
| Benirschke, K | 1 |
| Gee, NA | 1 |
| Lasley, BL | 3 |
| Pluchino, N | 1 |
| Santoro, A | 1 |
| Casarosa, E | 3 |
| Wenger, JM | 1 |
| Genazzani, AD | 2 |
| Petignat, P | 1 |
| Crawford, SL | 1 |
| McConnell, DS | 2 |
| Krishnan, S | 1 |
| Gustafson, MB | 1 |
| Campbell, C | 1 |
| Gaikwad, NW | 1 |
| Keim, NL | 1 |
| Archer, D | 1 |
| Bouchard, C | 2 |
| Fortier, M | 1 |
| Cusan, L | 2 |
| Gomez, JL | 1 |
| Girard, G | 1 |
| Baron, M | 1 |
| Ayotte, N | 1 |
| Moreau, M | 1 |
| Dubé, R | 1 |
| Labrie, C | 4 |
| Gilbert, L | 1 |
| Prati, A | 1 |
| Santagni, S | 1 |
| Rattighieri, E | 1 |
| Campedelli, A | 1 |
| Ricchieri, F | 1 |
| Chierchia, E | 1 |
| Despini, G | 1 |
| Konttinen, YT | 1 |
| Stegajev, V | 1 |
| Al-Samadi, A | 1 |
| Porola, P | 1 |
| Hietanen, J | 1 |
| Ainola, M | 1 |
| Beauregard, A | 1 |
| Hirokawa, K | 1 |
| Ohira, T | 1 |
| Nagayoshi, M | 1 |
| Kajiura, M | 1 |
| Imano, H | 1 |
| Kitamura, A | 1 |
| Kiyama, M | 1 |
| Okada, T | 1 |
| Iso, H | 1 |
| Gandhi, J | 1 |
| Chen, A | 1 |
| Dagur, G | 1 |
| Suh, Y | 1 |
| Smith, N | 1 |
| Cali, B | 1 |
| Khan, SA | 1 |
| Renner, L | 1 |
| Weiss, AR | 1 |
| Neuringer, M | 1 |
| Bélanger, A | 2 |
| Pelletier, G | 2 |
| Diamanti-Kandarakis, E | 1 |
| Dattilo, M | 1 |
| Macut, D | 1 |
| Duntas, L | 1 |
| Gonos, ES | 1 |
| Goulis, DG | 1 |
| Gantenbein, CK | 1 |
| Kapetanou, M | 1 |
| Koukkou, E | 1 |
| Lambrinoudaki, I | 1 |
| Michalaki, M | 1 |
| Eftekhari-Nader, S | 1 |
| Pasquali, R | 1 |
| Peppa, M | 1 |
| Tzanela, M | 1 |
| Vassilatou, E | 1 |
| Vryonidou, A | 1 |
| Crawford, S | 2 |
| Santoro, N | 2 |
| Laughlin, GA | 2 |
| Sowers, MF | 2 |
| McConnell, D | 1 |
| Sutton-Tyrrell, K | 1 |
| Weiss, G | 2 |
| Vuga, M | 1 |
| Randolph, J | 1 |
| Lasley, B | 1 |
| Mahmud, K | 1 |
| Collins, D | 1 |
| Younis, JS | 1 |
| Dickson, GM | 1 |
| Burd, ID | 1 |
| Bachmann, GA | 1 |
| Randolf, JF | 1 |
| Gold, EB | 1 |
| Baulieu, EE | 1 |
| Skałba, P | 1 |
| Wójtowicz, M | 1 |
| Sikora, J | 1 |
| Haller, U | 1 |
| Hepp, H | 1 |
| Winter, R | 1 |
| Luu-The, V | 1 |
| Simard, J | 1 |
| Lin, SX | 1 |
| Zouboulis, ChC | 1 |
| MARMORSTON, J | 1 |
| CROWLEY, LG | 1 |
| MYERS, SM | 1 |
| STERN, E | 1 |
| HOPKINS, CE | 1 |
| Nelson, DB | 1 |
| Sammel, MD | 1 |
| Freeman, EW | 1 |
| Gracia, CR | 1 |
| Liu, L | 1 |
| Langan, E | 1 |
| Cameron, DR | 1 |
| Braunstein, GD | 1 |
| Brandenburg, VM | 1 |
| Ketteler, M | 1 |
| Heussen, N | 1 |
| Politt, D | 1 |
| Frank, RD | 1 |
| Westenfeld, R | 1 |
| Ittel, TH | 1 |
| Floege, J | 1 |
| Arlt, W | 1 |
| Liu, JH | 1 |
| Lebrun, CE | 1 |
| van der Schouw, YT | 1 |
| de Jong, FH | 1 |
| Pols, HA | 1 |
| Grobbee, DE | 1 |
| Lamberts, SW | 2 |
| Goto, K | 1 |
| Yanase, T | 2 |
| Takayanagi, R | 2 |
| Nawata, H | 2 |
| Chahal, HS | 1 |
| Drake, WM | 1 |
| Tworoger, SS | 1 |
| Lee, IM | 1 |
| Buring, JE | 1 |
| Hankinson, SE | 1 |
| Coombes, RC | 3 |
| Chilvers, C | 1 |
| Dowsett, M | 10 |
| Gazet, JC | 2 |
| Ford, HT | 1 |
| Bettelheim, R | 1 |
| Gordon, C | 1 |
| Smith, IE | 8 |
| Zava, D | 1 |
| Powles, TJ | 2 |
| Bremond, AG | 1 |
| Claustrat, B | 1 |
| Rudigoz, RC | 1 |
| Seffert, P | 1 |
| Corniau, J | 1 |
| Harris, AL | 7 |
| Jeffcoate, SL | 5 |
| McKinna, JA | 1 |
| Morgan, M | 1 |
| Andersen, AN | 1 |
| Schiøler, V | 1 |
| Hertz, J | 1 |
| Bennett, P | 5 |
| Wilking, N | 1 |
| Carlström, K | 12 |
| Sköldefors, H | 1 |
| Theve, NO | 1 |
| Wallgren, A | 1 |
| Persky, H | 1 |
| Dreisbach, L | 1 |
| Miller, WR | 4 |
| O'Brien, CP | 1 |
| Khan, MA | 1 |
| Lief, HI | 1 |
| Charney, N | 1 |
| Strauss, D | 1 |
| Davidson, BJ | 1 |
| Riggs, BL | 1 |
| Wahner, HW | 1 |
| Judd, HL | 3 |
| Adami, HO | 1 |
| Axelsson, O | 1 |
| Vegelius, J | 1 |
| Akerström, G | 1 |
| Longcope, C | 3 |
| Bourget, C | 1 |
| Flood, C | 1 |
| Deslypere, JP | 1 |
| de Biscop, G | 1 |
| Vermeulen, A | 6 |
| Read, GF | 1 |
| Wilson, DW | 1 |
| Campbell, FC | 1 |
| Holliday, HW | 1 |
| Blamey, RW | 1 |
| Griffiths, K | 1 |
| Pelusi, G | 2 |
| Moretti, B | 2 |
| Martinelli, G | 2 |
| Camerini, T | 1 |
| Busacchi, P | 2 |
| Cavallina, R | 2 |
| Vikhliaeva, EM | 1 |
| Uvarova, EV | 1 |
| Talina, IS | 1 |
| Brody, S | 4 |
| von Uexküll, AK | 1 |
| Lagrelius, A | 7 |
| Lunell, NO | 7 |
| Rosenborg, L | 3 |
| Bonney, RC | 3 |
| Scanlon, MJ | 3 |
| Reed, MJ | 4 |
| Jones, DL | 4 |
| Beranek, PA | 2 |
| James, VH | 5 |
| Jeffcoate, S | 1 |
| Scaglia, HE | 1 |
| Koliren, L | 1 |
| Loruso, A | 1 |
| Zylbersztein, C | 1 |
| Ramos, G | 1 |
| Díaz, L | 1 |
| Soto, E | 1 |
| Skinner, SJ | 2 |
| Holdaway, IM | 2 |
| Mason, BH | 2 |
| Couch, RA | 1 |
| Kay, RG | 2 |
| Blackburn, AM | 1 |
| Wang, DY | 5 |
| Bulbrook, RD | 4 |
| Thomas, BS | 2 |
| Kwa, HG | 1 |
| Hoare, SA | 1 |
| Rubens, RD | 1 |
| Stuart-Harris, RC | 1 |
| Towobola, OA | 1 |
| Crilly, RC | 1 |
| Oakey, RE | 1 |
| Helgason, S | 2 |
| Damber, MG | 2 |
| Damber, JE | 1 |
| Selstam, G | 1 |
| von Schoultz, B | 5 |
| van Veelen, H | 1 |
| Willemse, PH | 1 |
| Sleijfer, DT | 1 |
| Pratt, JJ | 1 |
| Sluiter, WJ | 1 |
| Doorenbos, H | 1 |
| Meldrum, DR | 1 |
| Tataryn, IV | 1 |
| Frumar, AM | 1 |
| Erlik, Y | 1 |
| Lu, KH | 1 |
| Humeniuk, V | 1 |
| Kelly, RW | 1 |
| Mason, RC | 1 |
| Chetty, U | 1 |
| Hawkins, RA | 2 |
| Forrest, AP | 3 |
| Zumoff, B | 2 |
| Rosenfeld, RS | 2 |
| Strain, GW | 2 |
| Levin, J | 2 |
| Fukushima, DK | 2 |
| Chang, RJ | 1 |
| Crilly, RG | 3 |
| Francis, RM | 1 |
| Nordin, BE | 4 |
| Marshall, DH | 2 |
| Barkworth, SA | 1 |
| Markham, M | 1 |
| Worgul, TJ | 1 |
| Santen, RJ | 3 |
| Samojlik, E | 3 |
| Wells, SA | 2 |
| Bird, CE | 2 |
| Tremblay, J | 1 |
| Masters, V | 2 |
| Clark, AF | 2 |
| Cumming, DC | 1 |
| Rebar, RW | 1 |
| Hopper, BR | 1 |
| Yen, SS | 3 |
| Tanaka, S | 2 |
| Sakai, Y | 1 |
| Ikuyama, S | 1 |
| Haji, M | 1 |
| Baron, JA | 2 |
| Comi, RJ | 1 |
| Cryns, V | 1 |
| Brinck-Johnsen, T | 1 |
| Mercer, NG | 1 |
| Ebeling, P | 1 |
| Koivisto, VA | 1 |
| Massobrio, M | 1 |
| Migliardi, M | 1 |
| Cassoni, P | 1 |
| Menzaghi, C | 1 |
| Revelli, A | 1 |
| Cenderelli, G | 1 |
| Williams, DP | 1 |
| Boyden, TW | 1 |
| Pamenter, RW | 1 |
| Lohman, TG | 1 |
| Going, SB | 1 |
| Berge, LN | 1 |
| Lyngmo, V | 1 |
| Svensson, B | 1 |
| Nordøy, A | 1 |
| Hall, GM | 1 |
| Perry, LA | 2 |
| Spector, TD | 2 |
| Maggino, T | 2 |
| Marcadella, CB | 2 |
| Romagnolo, C | 2 |
| Bates, GW | 1 |
| Egerman, RS | 1 |
| Umstot, ES | 1 |
| Buster, JE | 1 |
| Casson, PR | 1 |
| Schmidt, PJ | 1 |
| Gindoff, PR | 1 |
| Baron, DA | 1 |
| Rubinow, DR | 1 |
| Cawood, EH | 2 |
| Bancroft, J | 2 |
| Lum, SS | 1 |
| Woltering, EA | 1 |
| Fletcher, WS | 1 |
| Pommier, RF | 1 |
| McNeil, C | 1 |
| Balint-Perić, LA | 1 |
| Prelević, GM | 1 |
| van den Beld, AW | 1 |
| van der Lely, AJ | 1 |
| Bernardi, F | 2 |
| Salvestroni, C | 1 |
| Tonetti, A | 1 |
| Luisi, S | 2 |
| Palumbo, M | 1 |
| Purdy, RH | 1 |
| Luisi, M | 2 |
| Katz, S | 1 |
| Morales, AJ | 1 |
| Sternon, J | 1 |
| Murakami, K | 1 |
| Nakagawa, T | 1 |
| Shozu, M | 1 |
| Uchide, K | 1 |
| Koike, K | 1 |
| Inoue, M | 1 |
| Tode, T | 1 |
| Kikuchi, Y | 1 |
| Hirata, J | 1 |
| Kita, T | 1 |
| Nakata, H | 1 |
| Nagata, I | 1 |
| Sengos, C | 1 |
| Iatrakis, G | 1 |
| Andreakos, C | 1 |
| Xygakis, A | 1 |
| Papapetrou, P | 1 |
| Phillips, TJ | 1 |
| Demircay, Z | 1 |
| Sahu, M | 1 |
| Monteleone, P | 1 |
| Stomati, M | 1 |
| Cobellis, L | 1 |
| Rose, DP | 2 |
| Davis, TE | 1 |
| Creel, RJ | 1 |
| Schindler, H | 1 |
| Koller, K | 1 |
| Hindy, I | 1 |
| Prajda, N | 1 |
| Tapolcsányi, L | 1 |
| Sellei, C | 1 |
| Eckhardt, S | 1 |
| Görlich, M | 1 |
| Heise, E | 1 |
| Hill, P | 1 |
| Wynder, EL | 1 |
| Helman, P | 1 |
| Hickman, R | 1 |
| Rona, G | 1 |
| Kuno, K | 1 |
| Poortman, J | 5 |
| Maroulis, GB | 2 |
| Abraham, GE | 2 |
| Duignan, NM | 1 |
| Jurczok, F | 1 |
| Hayward, JL | 2 |
| Kumaoka, S | 1 |
| Takatani, O | 1 |
| Abe, O | 1 |
| Utsunomiya, J | 1 |
| Borkowski, A | 1 |
| L'hermite, M | 1 |
| Dor, P | 1 |
| Longeval, E | 1 |
| Rozencweig, M | 1 |
| Muquardt, C | 1 |
| Van Cauter, E | 1 |
| Suy, E | 1 |
| Rubens, R | 1 |
| Holló, I | 2 |
| Szalay, F | 1 |
| Steczek, K | 1 |
| Szücs, J | 2 |
| Milewich, L | 1 |
| Gomez-Sanchez, C | 1 |
| Madden, JD | 1 |
| Bradfield, DJ | 1 |
| Parker, PM | 1 |
| Smith, SL | 1 |
| Carr, BR | 1 |
| Edman, CD | 1 |
| MacDonald, PC | 1 |
| Sansone-Bazzano, G | 1 |
| Seeler, AK | 1 |
| Cummings, B | 1 |
| Reisner, RM | 1 |
| Furuhjelm, M | 1 |
| Joelsson, I | 1 |
| Nyholm, H | 1 |
| Plesner, R | 1 |
| Abul-Hajj, YJ | 1 |
| Iverson, R | 1 |
| Kiang, DT | 1 |
| Thijssen, JH | 6 |
| Schwarz, F | 1 |
| Fern, M | 1 |
| Liskowski, L | 1 |
| Milbrath, JR | 1 |
| Lipton, A | 1 |
| Harvey, H | 1 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Franz, C | 1 |
| Watson, D | 1 |
| Montecucco, C | 1 |
| Caporali, R | 1 |
| Caprotti, P | 1 |
| Caprotti, M | 1 |
| Notario, A | 1 |
| Blankenstein, MA | 1 |
| Maitimu-Smeele, I | 1 |
| Donker, GH | 1 |
| Daroszewski, J | 1 |
| Milewicz, A | 1 |
| Bhatavdekar, JM | 1 |
| Patel, DD | 1 |
| Shah, NG | 1 |
| Giri, DD | 1 |
| Vora, HH | 1 |
| Karelia, NH | 1 |
| Trivedi, SN | 1 |
| Ghosh, N | 1 |
| Suthar, TP | 1 |
| Blaakaer, J | 1 |
| Djursing, H | 1 |
| Hørding, U | 1 |
| Toftager-Larsen, K | 1 |
| Bock, JE | 1 |
| Lebech, PE | 1 |
| Evans, TR | 1 |
| Di Salle, E | 1 |
| Ornati, G | 1 |
| Lassus, M | 1 |
| Benedetti, MS | 1 |
| Pianezzola, E | 1 |
| Adams, JB | 4 |
| Seymour-Munn, K | 1 |
| Deighton, CM | 1 |
| Watson, MJ | 1 |
| Walker, DJ | 1 |
| Astrup, A | 1 |
| Buemann, B | 1 |
| Christensen, NJ | 1 |
| Madsen, J | 1 |
| Gluud, C | 3 |
| Svenstrup, B | 3 |
| Mancini, A | 2 |
| di Pietro, C | 2 |
| de Marinis, L | 2 |
| Rossi, S | 2 |
| Lombardi, CP | 2 |
| Iacona, T | 1 |
| Bellantone, R | 2 |
| Liberale, I | 2 |
| Menini, E | 2 |
| Crucitti, F | 2 |
| De Pergola, G | 1 |
| Giagulli, VA | 2 |
| Garruti, G | 1 |
| Cospite, MR | 1 |
| Giorgino, F | 1 |
| Cignarelli, M | 1 |
| Giorgino, R | 2 |
| Hughes, CL | 1 |
| Wall, LL | 1 |
| Creasman, WT | 1 |
| Thompson, PW | 1 |
| McGarrigle, HH | 1 |
| Edwards, AC | 1 |
| Becker, U | 2 |
| Almdal, T | 1 |
| Christensen, E | 1 |
| Farholt, S | 2 |
| Hardt, F | 2 |
| Key, TJ | 2 |
| Pike, MC | 2 |
| Moore, JW | 2 |
| Micic, S | 1 |
| Rossmanith, WG | 1 |
| Scherbaum, WA | 1 |
| Lauritzen, C | 1 |
| Floreani, A | 1 |
| Titta, M | 1 |
| Plebani, M | 1 |
| Faggian, D | 1 |
| Chiaramonte, M | 1 |
| Naccarato, R | 1 |
| Gordon, GB | 1 |
| Bush, TL | 1 |
| Helzlsouer, KJ | 1 |
| Miller, SR | 1 |
| Comstock, GW | 1 |
| Mortola, JF | 1 |
| Liu, CH | 1 |
| Fischer, UG | 1 |
| Secreto, G | 1 |
| Toniolo, P | 1 |
| Pisani, P | 1 |
| Recchione, C | 1 |
| Cavalleri, A | 1 |
| Fariselli, G | 1 |
| Totis, A | 1 |
| Di Pietro, S | 1 |
| Berrino, F | 1 |
| Taelman, P | 1 |
| Kaufman, JM | 1 |
| Janssens, X | 1 |
| Steinberg, KK | 1 |
| Freni-Titulaer, LW | 1 |
| DePuey, EG | 1 |
| Miller, DT | 1 |
| Sgoutas, DS | 1 |
| Coralli, CH | 1 |
| Phillips, DL | 1 |
| Rogers, TN | 1 |
| Clark, RV | 1 |
| Möllerström, G | 2 |
| Rannevik, G | 3 |
| Verdonck, L | 1 |
| Deutsch, S | 1 |
| Benjamin, F | 1 |
| Seltzer, V | 1 |
| Tafreshi, M | 1 |
| Kocheril, G | 1 |
| Frank, A | 1 |
| Stuart-Harris, R | 1 |
| Hill, M | 1 |
| Cantwell, BM | 3 |
| Bannister, P | 1 |
| Sheridan, P | 1 |
| Losowsky, MS | 1 |
| Sterns, EE | 1 |
| Grio, R | 1 |
| Piacentino, R | 1 |
| Rustichelli, S | 1 |
| Marchino, GL | 1 |
| Zaccheo, F | 1 |
| Macchioni, S | 1 |
| van Landeghem, AA | 2 |
| Drife, JO | 1 |
| Goss, PE | 1 |
| Hutchison, G | 1 |
| Brodie, AM | 1 |
| Sainsbury, JR | 1 |
| Needham, G | 1 |
| Farndon, J | 1 |
| Wilson, R | 1 |
| Dogliotti, L | 2 |
| Orlandi, F | 2 |
| Torta, M | 2 |
| Buzzi, G | 2 |
| Naldoni, C | 2 |
| Mazzotti, A | 2 |
| Angeli, A | 2 |
| Friedman, AJ | 1 |
| Ravnikar, VA | 1 |
| Barbieri, RL | 1 |
| Lal, A | 1 |
| Devogelaer, JP | 1 |
| Crabbé, J | 1 |
| Nagant de Deuxchaisnes, C | 1 |
| Davis, MR | 1 |
| Veldhuis, JD | 1 |
| Rogol, AD | 1 |
| Dufau, ML | 1 |
| Catt, KJ | 1 |
| Jeppsson, S | 1 |
| Bjerre, B | 1 |
| Svanberg, L | 1 |
| Kaufman, FR | 1 |
| Donnell, GN | 1 |
| Lobo, RA | 1 |
| Heinonen, PK | 1 |
| Koivula, T | 1 |
| Pystynen, P | 1 |
| Barrett-Connor, E | 2 |
| Khaw, KT | 2 |
| Fehér, KG | 1 |
| Bencze, G | 1 |
| Ujfalussy, J | 1 |
| Fehér, T | 2 |
| Ribot, C | 1 |
| Tremollieres, F | 1 |
| Pouilles, JM | 1 |
| Bonneu, M | 1 |
| Germain, F | 1 |
| Louvet, JP | 1 |
| Tazuke, S | 1 |
| Sambrook, PN | 1 |
| Eisman, JA | 1 |
| Champion, GD | 1 |
| Pocock, NA | 1 |
| Boccardo, F | 1 |
| Valenti, G | 1 |
| Zanardi, S | 1 |
| Cerruti, G | 1 |
| Fassio, T | 1 |
| Bruzzi, P | 1 |
| De Franchis, V | 1 |
| Barreca, A | 1 |
| Del Monte, P | 1 |
| Minuto, F | 1 |
| Vermeulen-Meiners, C | 1 |
| Nabuurs, M | 2 |
| Pousette, A | 1 |
| Stege, R | 1 |
| Anderson, MC | 1 |
| Robertson, A | 1 |
| Seamark, RF | 1 |
| Bridges, A | 1 |
| Philcox, JC | 1 |
| Need, AG | 1 |
| Horowitz, M | 1 |
| Morris, HA | 1 |
| Deam, S | 1 |
| Ghilchik, MW | 1 |
| Argüelles, AE | 1 |
| Poggi, UL | 1 |
| Saborida, C | 1 |
| Hoffman, C | 1 |
| Chekherdemian, M | 1 |
| Blanchard, O | 1 |
| Sarfaty, G | 2 |
| Pitt, P | 1 |
| Tallis, M | 2 |
| Wong, MS | 1 |
| Sonka, J | 1 |
| Gregorová, I | 1 |
| Kölbel, F | 1 |
| Plotz, EJ | 1 |
| Wiener, M | 1 |
| Stein, AA | 1 |
| Hahn, BD | 1 |
| Nishida, E | 1 |
| Kuramoto, S | 1 |
| Barlow, JJ | 1 |
| Piro, C | 1 |
| Concolino, G | 1 |
| Conti, C | 1 |
| Nishida, A | 1 |
| Oertel, GW | 4 |
| Menzel, P | 2 |
| Schumann, C | 1 |
| Halberstadt, E | 1 |
| Taubert, HD | 1 |
| Procopé, BJ | 1 |
| Rieder, E | 1 |
| Rindt, W | 1 |
| Melville, E | 1 |
| Braunsberg, H | 1 |
| Bogdanova, AG | 1 |
| Gentile, JM | 1 |
| Aufiero, JF | 1 |
| Smud, R | 1 |
| Sermukslis, B | 1 |
| Barcza, B | 1 |
| Novak, ER | 1 |
| Goldberg, B | 1 |
| Jones, GS | 1 |
| O'Toole, RV | 1 |
| Stone, S | 1 |
| Kharma, KM | 1 |
| Nakamura, RM | 1 |
| Mishell, DR | 1 |
| Thorneycroft, IH | 1 |
| Saez, JM | 1 |
| Morera, AM | 1 |
| Dazord, A | 1 |
| Bertrand, J | 1 |
| Trybuchowski, H | 1 |
| Benes, P | 1 |
| Schirazi, M | 1 |
| Holzmann, H | 1 |
| Hoffmann, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause[NCT03854396] | Phase 3 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to due to termination of ISR by PI with agreement by grant sponsor) | ||
| Open-Label Vulvoscopy Photography Study of Changes in Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Administration of 6.5 Mg Vaginal Prasterone in Menopausal Women With Moderate to Severe Dyspareunia[NCT03568604] | Phase 4 | 18 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)[NCT01846442] | Phase 3 | 218 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Review on the Clinical Outcome of Chinese Women With Moderate to Severe Symptoms of Genitourinary Syndrome of Menopause (GSM) Treated With Vaginal Dehydroepiandrosterone (DHEA)[NCT05434351] | 4 participants (Actual) | Observational | 2022-08-01 | Terminated (stopped due to inadequate sample and only few patients were prescribed with vaginal DHEA) | |||
| Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)[NCT03740945] | Phase 3 | 0 participants (Actual) | Interventional | 2018-11-06 | Withdrawn (stopped due to Business decision to not perform this study.) | ||
| DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)[NCT01256684] | Phase 3 | 255 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy[NCT03782480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-03-02 | Recruiting | ||
| [NCT02013544] | Phase 3 | 558 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause[NCT05483634] | 40 participants (Anticipated) | Observational | 2022-10-28 | Not yet recruiting | |||
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman: A Randomized Placebo-controlled Trial[NCT05627791] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2022-11-30 | Terminated (stopped due to Unable to recuit participant number in time.) | ||
| Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women: Randomized and Controlled Trial.[NCT04487392] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-15 | Withdrawn (stopped due to The student do not start the study) | ||
| DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study.[NCT00429806] | Phase 1 | 40 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| To Investigate the Effectiveness of Adjuvant Supplements Prior to in Vitro Fertilization Cycles[NCT05471453] | 90 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| Antioxidants vs.Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve[NCT03621683] | 78 participants (Actual) | Interventional | 2016-01-06 | Completed | |||
| DHEA + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women (Placebo Controlled, Double Blind and Randomized Phase III Study to Evaluate the Effects of 12-Week Treatment With DHEA (Prasterone) and Acolbifene on Vasomotor Symptoms (H[NCT01452373] | Phase 3 | 238 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.[NCT00248989] | Phase 3 | 150 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| Assessment and Augmentation of Lip Appearance in Specific Study Populations[NCT04839692] | Phase 4 | 37 participants (Actual) | Interventional | 2021-05-07 | Completed | ||
| The Effects of Testosterone and Nutritional Supplementation, Alone and Combined, on the Adverse Effects of Under-Nutrition in the Elderly[NCT00117000] | Phase 3 | 200 participants | Interventional | 2003-07-31 | Active, not recruiting | ||
| Pituitary Gonadotropin Response to GnRH Stimulation in Menstrual, Climacteric and, Menopause-Related Mood and Behavioral Disorders[NCT00001232] | 140 participants | Observational | 1988-07-31 | Completed | |||
| Predicting Adaptive Thermogenesis[NCT00687115] | Phase 2 | 83 participants (Actual) | Interventional | 2008-09-18 | Completed | ||
| Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women[NCT00317148] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 3.0 | 2.0 | -1.0 |
| 0.50% DHEA | 3.1 | 1.8 | -1.3 |
| 1.00% DHEA | 3.1 | 1.6 | -1.5 |
| Placebo | 3.1 | 2.7 | -0.5 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.7 | 1.7 | -1.0 |
| 0.50% DHEA | 2.8 | 1.5 | -1.3 |
| 1.00% DHEA | 2.7 | 1.4 | -1.3 |
| Placebo | 2.8 | 2.4 | -0.4 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal epithelial surface thickness(one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.9 | 1.9 | -1.0 |
| 0.50% DHEA | 3.1 | 1.8 | -1.3 |
| 1.00% DHEA | 3.0 | 1.6 | -1.4 |
| Placebo | 3.0 | 2.6 | -0.4 |
To evaluate the aspect of the vaginal mucosa and the local tolerance to DHEA suppository, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 3.1 | 1.9 | -1.2 |
| 0.50% DHEA | 3.2 | 1.8 | -1.4 |
| 1.00% DHEA | 3.0 | 1.5 | -1.4 |
| Placebo | 3.1 | 2.7 | -0.4 |
The severity of dyspareunia was evaluated by a questionnaire. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 2.8 | 1.4 | -1.3 |
| 0.50% DHEA | 2.7 | 1.1 | -1.6 |
| 1.00% DHEA | 2.6 | 1.2 | -1.4 |
| Placebo | 2.8 | 2.3 | -0.4 |
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | percentage of parabasal cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 65.5 | 16.9 | -48.6 |
| 0.50% DHEA | 53.4 | 11.0 | -42.4 |
| 1.00% DHEA | 61.8 | 6.90 | -54.9 |
| Placebo | 46.7 | 47.8 | 1.1 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | percentage of superficial cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 0.4 | 5.7 | 5.3 |
| 0.50% DHEA | 0.4 | 5.2 | 4.8 |
| 1.00% DHEA | 0.4 | 6.5 | 6.1 |
| Placebo | 0.6 | 0.5 | -0.1 |
A pH strip was applied directly to the lateral wall of the vagina using forceps. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01846442)
Timeframe: Baseline and Week 12
| Intervention | pH (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline | |
| 0.25% DHEA | 6.6 | 5.5 | -1.1 |
| 0.50% DHEA | 6.6 | 5.2 | -1.5 |
| 1.00% DHEA | 6.5 | 5.1 | -1.4 |
| Placebo | 6.5 | 6.0 | -0.5 |
The percentage of parabasal cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | Percentage of parabasal cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 65.72 | 28.43 | -37.29 |
| 0.50% DHEA | 65.05 | 17.65 | -47.40 |
| Placebo | 68.48 | 66.86 | -1.62 |
The percentage of superficial cell was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including the basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | Percentage of superficial cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 0.68 | 5.43 | 4.75 |
| 0.50% DHEA | 0.68 | 6.30 | 5.62 |
| Placebo | 0.73 | 1.64 | 0.91 |
The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.56 | 1.54 | -1.01 |
| 0.50% DHEA | 2.63 | 1.36 | -1.27 |
| Placebo | 2.58 | 1.71 | -0.87 |
To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.94 | 2.27 | -0.67 |
| 0.50% DHEA | 2.94 | 2.05 | -0.89 |
| Placebo | 2.82 | 2.56 | -0.26 |
To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.57 | 1.92 | -0.65 |
| 0.50% DHEA | 2.57 | 1.69 | -0.88 |
| Placebo | 2.58 | 2.13 | -0.45 |
To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.90 | 2.32 | -0.58 |
| 0.50% DHEA | 2.89 | 2.14 | -0.75 |
| Placebo | 2.91 | 2.57 | -0.34 |
To evaluate the aspect of the mucosa and the local tolerance to DHEA suppositories, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were then analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.81 | 2.10 | -0.71 |
| 0.50% DHEA | 2.83 | 1.95 | -0.88 |
| Placebo | 2.78 | 2.36 | -0.42 |
The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 2.20 | 0.91 | -1.29 |
| 0.50% DHEA | 2.37 | 0.92 | -1.45 |
| Placebo | 2.33 | 1.32 | -1.02 |
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT01256684)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.25% DHEA | 6.48 | 5.70 | -0.77 |
| 0.50% DHEA | 6.47 | 5.43 | -1.04 |
| Placebo | 6.51 | 6.31 | -0.21 |
The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | Percentage of parabasal cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 54.25 | 12.74 | -41.51 |
| Placebo | 51.66 | 39.68 | -11.98 |
The percentage of superficial cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | Percentage of superficial cells (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 1.02 | 11.22 | 10.20 |
| Placebo | 1.04 | 2.78 | 1.75 |
The severity of dyspareunia was evaluated by a questionnaire filled out by women. The severity of dyspareunia recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.54 | 1.13 | -1.42 |
| Placebo | 2.56 | 1.50 | -1.06 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal color (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.75 | 2.03 | -0.73 |
| Placebo | 2.67 | 2.34 | -0.33 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial integrity (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.45 | 1.75 | -0.69 |
| Placebo | 2.43 | 2.06 | -0.37 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal epithelial surface thickness (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy was analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.83 | 2.09 | -0.74 |
| Placebo | 2.76 | 2.41 | -0.36 |
To evaluate the aspect of the mucosa and the local tolerance to prasterone ovules, the vaginal secretions (one of the four main signs of vaginal atrophy) evaluated by the physician/gynecologist as corresponding to none, mild, moderate, or severe atrophy were analyzed using the score values of 1, 2, 3 and 4, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.70 | 1.97 | -0.73 |
| Placebo | 2.63 | 2.24 | -0.39 |
The severity of vaginal dryness was evaluated by a questionnaire filled out by women. The severity of vaginal dryness recorded as none, mild, moderate or severe was analyzed using the score values of 0, 1, 2 or 3, respectively. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 2.30 | 0.86 | -1.44 |
| Placebo | 2.30 | 1.13 | -1.17 |
A pH strip fixed on an Ayre spatula (or equivalent) was applied directly to the lateral wall of the vagina. The change in color of the pH indicator strip was compared to the color chart for pH evaluation. The corresponding pH value (with one decimal) was recorded. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented. (NCT02013544)
Timeframe: Baseline and Week 12
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 12 | Change from Baseline to Week 12 | |
| 0.50% Prasterone (DHEA) | 6.34 | 5.39 | -0.94 |
| Placebo | 6.32 | 6.05 | -0.27 |
"Pre and post-treatment lip vessel thickness was measured in µm using Optical Coherence Tomography-Angiography imaging. For each age group, pre and post-treatment means were calculated.~The difference between the post and the pre-treatment means is shown below (post-treatment mean - pre-treatment mean)." (NCT04839692)
Timeframe: Day 1 and Day 14
| Intervention | µm (Mean) |
|---|---|
| Young Females (21-30 Years Old) | 0.833 |
| Post Menopausal Females | 0.360 |
"The Lip Fullness Grading Scale was used to measure the size of the lips before and after the procedure in both groups. The result presented below is the difference between the means after and before the procedures for each group.~min value: 0 - very thin lips - worse outcome Max value: 4 - full lips- a better outcome" (NCT04839692)
Timeframe: D1 and D14
| Intervention | units on a scale (Mean) |
|---|---|
| Young Females (21-30 Years Old) | 1.14 |
| Post Menopausal Females | 0.78 |
This scale will be used to record the subject's overall pain from the procedure. There are 6 faces ranging from 0=no pain to 10=the worst pain. (NCT04839692)
Timeframe: Day 1
| Intervention | score on a scale (Mean) |
|---|---|
| Young Females (21-30 Years Old) | 2.9 |
| Post Menopausal Females | 3.5 |
48 reviews available for dehydroepiandrosterone and Menopause
| Article | Year |
|---|---|
Revisiting the physiological role of androgens in women.
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Menopause; Menstrual Cycle; Pregnancy | 2022 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
Current challenges in the pharmacological management of genitourinary syndrome of menopause.
Topics: Atrophy; Breast Neoplasms; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Quality of | 2023 |
The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe | 2023 |
Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review.
Topics: Dehydroepiandrosterone; Estrogens; Female; Humans; Hyaluronic Acid; Menopause; Testosterone; Vagina | 2023 |
A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors.
Topics: Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Ne | 2023 |
An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Androgens; Atrophy; Dehydroepiandrosterone; Dyspareunia; Estrogens; Fe | 2020 |
Drugs for menopausal symptoms.
Topics: Animals; Cimicifuga; Dehydroepiandrosterone; Estrogens; Female; Flax; Hot Flashes; Humans; Menopause | 2020 |
Postmenopausal Hormone Therapy-Local and Systemic: A Pharmacologic Perspective.
Topics: Dehydroepiandrosterone; Estrogen Replacement Therapy; Estrogens; Female; Female Urogenital Diseases; | 2020 |
Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
Topics: Bayes Theorem; Dehydroepiandrosterone; Estrogens; Female; Female Urogenital Diseases; Humans; Laser | 2021 |
Genitourinary Syndrome of Menopause.
Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Es | 2018 |
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus | 2019 |
Optimizing quality of life through sex steroids by their effects on neurotransmitters.
Topics: Aging; Dehydroepiandrosterone; Female; Gonadal Steroid Hormones; Humans; Menopause; Nervous System P | 2019 |
Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estrogens; Female; | 2019 |
Androgen use for low sexual desire in midlife women.
Topics: Androgens; Dehydroepiandrosterone; Female; Humans; Menopause; Middle Aged; Sex Hormone-Binding Globu | 2013 |
Advances in neurosteroids: role in clinical practice.
Topics: Affect; Aging; Behavior; Brain Injuries; Cognition; Dehydroepiandrosterone; Dehydroepiandrosterone S | 2013 |
All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
Topics: Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Estrogen Receptor Modulators; Estrog | 2015 |
[The putative role and use of DHEA and its association with the hormone replacement therapy].
Topics: Aging; Dehydroepiandrosterone; Female; Hormone Replacement Therapy; Humans; Menopause | 2014 |
Sjögren's syndome and extragonadal sex steroid formation: a clue to a better disease control?
Topics: Androgens; Autoimmunity; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dendritic Cells; Di | 2015 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management.
Topics: Atrophic Vaginitis; Dehydroepiandrosterone; Dyspareunia; Estrogen Replacement Therapy; Female; Human | 2016 |
Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology.
Topics: Androgens; Animals; Atrophy; Dehydroepiandrosterone; Estrogens; Female; Gonadal Steroid Hormones; Hu | 2017 |
MECHANISMS IN ENDOCRINOLOGY: Aging and anti-aging: a Combo-Endocrinology overview.
Topics: Adjuvants, Immunologic; Aging; Androgens; Antioxidants; Circadian Rhythm; Dehydroepiandrosterone; Di | 2017 |
Ovarian aging and implications for fertility female health.
Topics: Adult; Aging; Dehydroepiandrosterone; Diagnostic Techniques, Obstetrical and Gynecological; Female; | 2012 |
DHEA and intracrinology at menopause, a positive choice for evolution of the human species.
Topics: Adult; Age Factors; Aging; Androgens; Biological Evolution; Dehydroepiandrosterone; Endometrium; Est | 2013 |
Androgen replacement in menopause.
Topics: Androgens; Androstenedione; Bone Density; Dehydroepiandrosterone; Female; Hormone Replacement Therap | 2001 |
Androgens and aging men.
Topics: Aging; Androgens; Bone Density; Dehydroepiandrosterone; Estradiol; Female; Humans; Libido; Male; Men | 2002 |
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Adult; Aged; Aged, 80 and over; Androgens; Animals; Bone Density; | 2003 |
Extragonadal synthesis of sex steroids: intracrinology.
Topics: Adult; Aged; Cytochrome P-450 Enzyme System; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 2003 |
The role of androgens in female sexual dysfunction.
Topics: Administration, Cutaneous; Administration, Oral; Androgens; Arousal; Chemistry, Pharmaceutical; Clin | 2004 |
The use of dehydroepiandrosterone therapy in clinical practice.
Topics: Adrenal Insufficiency; Aging; Alzheimer Disease; Bone Density; Cardiovascular Diseases; Dehydroepian | 2005 |
Androgen therapy in women.
Topics: Adolescent; Adrenal Glands; Adult; Aged; Androgens; Dehydroepiandrosterone; Female; Hormone Replacem | 2006 |
[Adrenal androgen and bone metabolism].
Topics: Bone and Bones; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estrogens; Fem | 2006 |
The endocrine system and ageing.
Topics: Aging; Androgens; Dehydroepiandrosterone; Endocrine System; Female; Gonadotropins, Pituitary; Hormon | 2007 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
The ovary after menopause.
Topics: Androgens; Androstenedione; Dehydroepiandrosterone; Estradiol; Estrogens; Female; Humans; Menopause; | 1981 |
Steroid hormones, ageing and bone.
Topics: Adult; Aged; Aging; Androstenedione; Bone and Bones; Calcium; Castration; Dehydroepiandrosterone; Es | 1981 |
Aromatase in bone cell: association with osteoporosis in postmenopausal women.
Topics: Aged; Androstenedione; Animals; Aromatase; Base Sequence; Bone and Bones; Bone Density; Calcitriol; | 1995 |
Physiological importance of dehydroepiandrosterone.
Topics: Breast Neoplasms; Cardiovascular Diseases; Dehydroepiandrosterone; Female; Humans; Insulin Resistanc | 1994 |
The endocrinology of aging.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Aging; Animals; Climacteric; Dehydroepiandrosterone; Endocr | 1997 |
Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause.
Topics: Adult; Aging; Animals; Bone Remodeling; Cardiovascular System; Dehydroepiandrosterone; Estrogen Repl | 1998 |
Hormonal effects on skin aging.
Topics: Dehydroepiandrosterone; Estrogens; Female; Growth Hormone; Hormone Replacement Therapy; Hot Flashes; | 2001 |
Clinical implications of circulating neurosteroids.
Topics: Aging; Alzheimer Disease; Dehydroepiandrosterone; Female; Humans; Male; Menopause; Menstrual Cycle; | 2001 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
Human breast cancer: concerted role of diet, prolactin and adrenal C19-delta 5-steroids in tumorigenesis.
Topics: Adrenal Glands; Animals; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; D | 1992 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Intracrinology.
Topics: Adrenal Glands; Androgens; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1991 |
Breast development in puberty.
Topics: Adipose Tissue; Adolescent; Adult; Androgens; Breast; Breast Neoplasms; Cell Differentiation; Cell D | 1986 |
Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; | 1985 |
Adrenal and gonadal androgen secretion in normal females.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Androstenedione; Dehydroepiandrosterone; Deh | 1986 |
[Biochemical and clinical aspects of dehydroepiandrosterone].
Topics: Androgens; Chemical Phenomena; Chemistry; Dehydroepiandrosterone; Erythrocytes; Estrogens; Female; G | 1971 |
16 trials available for dehydroepiandrosterone and Menopause
| Article | Year |
|---|---|
Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?
Topics: Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Dyspareunia; Female; Humans; Menopaus | 2022 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Dehyd | 2018 |
Association between circulating endogenous androgens and insulin sensitivity changes with exercise training in midlife women.
Topics: Adult; Androgens; Blood Glucose; Body Composition; Cardiovascular Diseases; Cholesterol; Dehydroepia | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
Topics: Administration, Intravaginal; Adult; Aged; Androgens; Arousal; Dehydroepiandrosterone; Double-Blind | 2014 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Topics: Administration, Intravaginal; Adult; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; | 2015 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Topics: Administration, Intravaginal; Aged; Dehydroepiandrosterone; Double-Blind Method; Dyspareunia; Female | 2016 |
A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Androgens; Dehydroepiandrosterone | 2017 |
A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Androgens; Dehydroepiandrosterone | 2017 |
A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Androgens; Dehydroepiandrosterone | 2017 |
A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Androgens; Dehydroepiandrosterone | 2017 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; | 1982 |
Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1983 |
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1984 |
Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1984 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women.
Topics: Adult; Aged; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Humans; Insulin; Meno | 1995 |
Potential drug DHEA hits snags on way to clinic.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; Female; Humans; Male; Menopause; | 1997 |
Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Topics: Aged; Androstadienes; Androstenedione; Aromatase Inhibitors; Dehydroepiandrosterone; Estrogens; Fema | 1992 |
The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women.
Topics: Administration, Oral; Adrenal Glands; Aged; Aging; Androgens; Body Weight; Dehydroepiandrosterone; D | 1990 |
198 other studies available for dehydroepiandrosterone and Menopause
| Article | Year |
|---|---|
Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause.
Topics: Atrophy; Consensus; Dehydroepiandrosterone; Female; Female Urogenital Diseases; Humans; Menopause; S | 2022 |
Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
Topics: Aromatase Inhibitors; Atrophy; Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estradiol | 2022 |
What is the role of dehydroepiandrosterone in gynecologic practice?
Topics: Administration, Intravaginal; Administration, Oral; Atrophy; Dehydroepiandrosterone; Dyspareunia; Fe | 2019 |
Does Type of Menopause Affect the Sex Lives of Women?
Topics: Adult; Coitus; Dehydroepiandrosterone; Female; Follicle Stimulating Hormone; Humans; Libido; Menopau | 2020 |
Effects of Ziyin Jianghuo Ningxin decoction plus dehydroepiandrosterone and femoston in treatment of patients with menopausal symptoms.
Topics: Adult; Bone Density; Dehydroepiandrosterone; Drug Therapy, Combination; Drugs, Chinese Herbal; Estra | 2018 |
Insight on the Intracrinology of Menopause: Androgen Production within the Human Vagina.
Topics: Aged; Aged, 80 and over; Androgens; Dehydroepiandrosterone; Female; Gene Expression; Humans; Menopau | 2021 |
Circulating sex-steroids and Staphylococcus aureus nasal carriage in a general female population.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Carrier State; Dehydroepiandrosterone; Female; Gona | 2021 |
Effect of short-term DHEA supplementation on serum and hippocampal estrogen concentrations in perimenopausal female rhesus macaques.
Topics: Administration, Oral; Animals; Dehydroepiandrosterone; Dietary Supplements; Estradiol; Estrogens; Fe | 2017 |
Dehydroepiandrosterone use in postmenopausal women: an androgenic option for managing sexual pain caused by vulvovaginal atrophy.
Topics: Atrophy; Dehydroepiandrosterone; Female; Humans; Menopause; Pain; Postmenopause | 2017 |
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
Topics: Administration, Intravaginal; Aged; Androgens; Atrophy; Consensus; Dehydroepiandrosterone; Dyspareun | 2018 |
Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues.
Topics: Aged; Androgens; Dehydroepiandrosterone; Endocrinology; Estradiol; Estrogens; Female; Humans; Hymen; | 2019 |
Prasterone: A Review in Vulvovaginal Atrophy.
Topics: Administration, Intravaginal; Atrophy; Clinical Trials, Phase III as Topic; Dehydroepiandrosterone; | 2019 |
Newer Name, Newer Treatments: The Genitourinary Syndrome of Menopause.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Atrophy; Dehydroepiandrosterone; Estrogens; Fe | 2019 |
Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.
Topics: Adrenal Glands; Aging; Androgens; Androstenediol; Animals; Dehydroepiandrosterone; Dehydroepiandrost | 2013 |
Ovarian adrenal interactions during the menopausal transition.
Topics: Androgens; Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Humans; Menopause; Testo | 2013 |
Dehydroepiandrosterone-sulfate is associated with cardiovascular reactivity to stress in women.
Topics: Adult; Age Factors; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; Cardiovascular Phy | 2016 |
Cognition in aged rhesus monkeys: effect of DHEA and correlation with steroidogenic gene expression.
Topics: Age Factors; Animals; Cognition; Dehydroepiandrosterone; Estradiol; Female; Gene Expression; Hippoca | 2017 |
Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition.
Topics: Adult; Aging; Asian People; Black or African American; Cross-Sectional Studies; Dehydroepiandrostero | 2009 |
Natural hormone therapy for menopause.
Topics: Adult; Aged; Cognition; Dehydroepiandrosterone; Estradiol; Estriol; Female; Hormone Replacement Ther | 2010 |
Bioidentical hormone therapy. An overview of benefits and prescribing guidance.
Topics: Dehydroepiandrosterone; Estrogens; Female; Hormones; Humans; Male; Menopause; Postmenopause; Progest | 2008 |
DHEA, important source of sex steroids in men and even more in women.
Topics: Adrenal Glands; Age Factors; Aging; Anticarcinogenic Agents; Brain; Breast; Cardiovascular Diseases; | 2010 |
Menopause management: how you can do better.
Topics: Acupuncture Therapy; Adjuvants, Immunologic; Administration, Cutaneous; Administration, Topical; Aff | 2012 |
The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity.
Topics: Adult; Age Distribution; Asian People; Black People; Body Mass Index; Cohort Studies; Dehydroepiandr | 2002 |
Androgen and SHBG serum concentrations in late post-menopause women.
Topics: Adult; Aged; Androgens; Androstenedione; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepi | 2003 |
[Anti-aging or better aging: a contribution to the prevention of aging?].
Topics: Aging; Dehydroepiandrosterone; Female; Genetic Testing; Hormones; Humans; Menopause | 2003 |
[Intrinsic skin aging. A critical appraisal of the role of hormones].
Topics: Administration, Topical; Adolescent; Adult; Age Factors; Aged; Androgens; Antioxidants; Chemexfoliat | 2003 |
I. URINARY EXCRETION OF NEUTRAL 17-KETOSTEROIDS AND PREGNANDEIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE.
Topics: 17-Ketosteroids; Androsterone; Breast Diseases; Breast Neoplasms; Dehydroepiandrosterone; Etiocholan | 1965 |
Tubal ligation does not affect hormonal changes during the early menopausal transition.
Topics: Adult; Anxiety; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone; Follow-Up S | 2005 |
Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones.
Topics: Adult; Aged; Anti-Inflammatory Agents; Bone Density; Dehydroepiandrosterone; Estradiol; Female; Foll | 2005 |
Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
Topics: Androgens; Dehydroepiandrosterone; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy | 2005 |
Relations between body composition, functional and hormonal parameters and quality of life in healthy postmenopausal women.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Androstenedione; Body Composition; Cross-Sectional Stu | 2006 |
Plasma androgen concentrations and risk of incident ovarian cancer.
Topics: Adult; Age of Onset; Aged; Androgens; Androstenedione; Case-Control Studies; Cohort Studies; Dehydro | 2008 |
Estradiol, androstenedione, testosterone, and dehydroepiandrosterone sulfate in the ovarian and peripheral blood of postmenopausal patients with and without endometrial cancer.
Topics: Aged; Androstenedione; Dehydroepiandrosterone; Estradiol; Female; Gonadal Steroid Hormones; Humans; | 1982 |
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandro | 1982 |
Effect of metoclopramide induced hyperprolactinaemia on the gonadotrophic response to oestradiol and LRH.
Topics: Adult; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Estradiol; Female; Follicle Stimula | 1982 |
Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrogens; Estrone; Fe | 1982 |
The relation of plasma androgen levels to sexual behaviors and attitudes of women.
Topics: Adult; Age Factors; Androgens; Androstenedione; Arousal; Attitude; Coitus; Dehydroepiandrosterone; F | 1982 |
Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures.
Topics: Androgens; Androstenedione; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1983 |
Serum levels of cortisol, dehydroepiandrosterone, dehydroepiandrosterone sulphate, estrone and prolactin after surgical trauma in postmenopausal women.
Topics: Adrenal Cortex Hormones; Aged; Cholecystectomy; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfa | 1982 |
The production and aromatization of dehydroepiandrosterone in post-menopausal women.
Topics: Aged; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Metabolic Clearance Rate; Middle | 1982 |
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Cos | 1983 |
Seasonal variation of plasma dehydroepiandrosterone sulphate and urinary androgen excretion in post-menopausal women.
Topics: Adrenal Cortex; Aged; Androgens; Androstane-3,17-diol; Androsterone; Dehydroepiandrosterone; Dehydro | 1983 |
Salivary cortisol and dehydroepiandrosterone sulphate levels in postmenopausal women with primary breast cancer.
Topics: Aged; Breast Neoplasms; Circadian Rhythm; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Fe | 1983 |
Behavior of some steroids in endometrial adenomatous and atypical hyperplasia.
Topics: Adult; Androgens; Androstenedione; Dehydroepiandrosterone; Endometrial Hyperplasia; Estradiol; Estro | 1983 |
Androgen secretion after age 50 in both sexes.
Topics: Adrenal Glands; Aged; Aging; Androgens; Chorionic Gonadotropin; Dehydroepiandrosterone; Female; Huma | 1983 |
Clinical and metabolic effects of Gynodian-depot in vegetoneurotic disorders following removal of uterine myoma in menopausal patients.
Topics: Climacteric; Dehydroepiandrosterone; Drug Combinations; Estradiol; Female; Gonadotropins, Pituitary; | 1983 |
Peripheral hormone levels and the endometrial condition in postmenopausal women.
Topics: Body Weight; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endometrium; Estradiol; Estroge | 1983 |
Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Adult; Aged; Androstenediol; Androstenediols; Brea | 1984 |
Adrenal androgen concentrations in endometrium and plasma during the menstrual cycle.
Topics: Adult; Androstenediol; Androstenediols; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Endo | 1984 |
Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Topics: Adult; Aged; Aldosterone; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dehydroepiandrosteron | 1984 |
Estrogen receptor status, adrenal androgens and 7 alpha-hydroxydehydroepiandrosterone in breast cancer patients.
Topics: Age Factors; Aged; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; | 1984 |
Oestrone sulphate in plasma from postmenopausal women and the effects of oestrogen and androgen therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Castration; Dehydroepiandrosterone; Estradiol; Estrogens; Estr | 1980 |
Adrenal steroids, bone mineral content and endometrial pathology in postmenopausal women.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Bone and Bones; Dehydroepiandrosterone; Dehydr | 1981 |
Effects of various oestrogens on circulating androgens and cortisol during replacement therapy in post-menopausal women.
Topics: Aged; Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dose-Respo | 1981 |
Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
Topics: Adrenocorticotropic Hormone; Aged; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Estradi | 1982 |
Adrenocortical steroids, bone mineral content and endometrial condition in post-menopausal women.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Bone and Bones; Dehydroepiandrosterone; Estron | 1982 |
Behaviour of some steroids in postmenopausal women with coelomic ovarian tumors.
Topics: Adenocarcinoma, Mucinous; Androstenedione; Carcinoma; Dehydroepiandrosterone; Dehydroepiandrosterone | 1983 |
Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.
Topics: Adrenocorticotropic Hormone; Aged; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Female | 1984 |
Gonadotropins, estrogens, and adrenal steroids during the menopausal hot flash.
Topics: Androstenedione; Body Temperature; Dehydroepiandrosterone; Estradiol; Estrone; Female; Follicle Stim | 1980 |
Dehydroepiandrosterone sulphate in breast secretions.
Topics: Androsterone; Breast; Cross Reactions; Dehydroepiandrosterone; Female; Gas Chromatography-Mass Spect | 1980 |
Aminoglutethimide and advanced breast cancer [proceedings].
Topics: Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Female; Humans; Kinetics; Menopause; Re | 1980 |
Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults.
Topics: Adult; Age Factors; Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; Ma | 1980 |
Treatment with oral estrone sulphate in the female climacteric. II. Hormonal aspects.
Topics: Adult; Climacteric; Dehydroepiandrosterone; Estrogens; Estrone; Female; Follicle Stimulating Hormone | 1981 |
Oestrogens, the menopause and the adrenopause.
Topics: Adrenal Glands; Adult; Age Factors; Androgens; Androstenedione; Castration; Dehydroepiandrosterone; | 1981 |
Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer.
Topics: Adult; Age Factors; Aged; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Female; Humans; Me | 1981 |
How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Topics: Adrenalectomy; Aged; Aldosterone; Androgens; Androstenedione; Breast Neoplasms; Dehydroepiandrostero | 1982 |
Delta 5-androstenediol: kinetics of metabolism and binding to plasma proteins in normal post-menopausal women.
Topics: Aged; Androstenediol; Androstenediols; Androstenedione; Androsterone; Blood Proteins; Dehydroepiandr | 1982 |
Evidence for an influence of the ovary on circulating dehydroepiandrosterone sulfate levels.
Topics: Adult; Aged; Castration; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; | 1982 |
The effect of cigarette smoking on adrenal cortical hormones.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Androstenedione; Dehydro | 1995 |
The relationship of urinary and plasma androgens to steroid receptors and menopausal status in breast cancer patients and their influence on survival.
Topics: 17-Hydroxycorticosteroids; Adult; Aged; Androgens; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydro | 1994 |
Steroid gradients across the cancerous breast: an index of altered steroid metabolism in breast cancer?
Topics: Adult; Aged; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfa | 1994 |
Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females.
Topics: Adipose Tissue; Adult; Aging; Body Composition; Body Mass Index; Dehydroepiandrosterone; Dehydroepia | 1993 |
The bleeding time in women: an influence of the sex hormones?
Topics: Adult; Bleeding Time; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Estriol; Fe | 1993 |
Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; E | 1993 |
The role of insulin and renin in the pathogenesis of hormone-dependent neoplasias. b). Renin.
Topics: Adipose Tissue; Androstenedione; Blood Pressure; Breast Neoplasms; Dehydroepiandrosterone; Endometri | 1993 |
The role of insulin and renin in the pathogenesis of hormone-dependent neoplasias. a). Insulin.
Topics: Androstenedione; Blood Glucose; Body Weight; Breast Neoplasms; Dehydroepiandrosterone; Endometrial N | 1993 |
Basal and stimulated gonadotropin levels in the perimenopause.
Topics: Adult; Analysis of Variance; Dehydroepiandrosterone; Estradiol; Female; Follicle Stimulating Hormone | 1996 |
Steroid hormones, the menopause, sexuality and well-being of women.
Topics: Adult; Affect; Analysis of Variance; Chi-Square Distribution; Climacteric; Dehydroepiandrosterone; D | 1996 |
Androgens and the menopause; a study of 40-60-year-old women.
Topics: Adrenal Glands; Adult; Age Factors; Androgens; Androstenedione; Body Mass Index; Dehydroepiandroster | 1996 |
Changes in serum estrogen levels in women during tamoxifen therapy.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrogens; Estr | 1997 |
Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment.
Topics: Adult; Calcitonin; Dehydroepiandrosterone; Drug Combinations; Estradiol; Female; Follicle Stimulatin | 1997 |
Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aged; Aging; Corticotropin-Releasing Hormone; De | 1998 |
[Rejuvenating hormones].
Topics: Antioxidants; Climacteric; Dehydroepiandrosterone; Estrogen Replacement Therapy; Female; Free Radica | 1999 |
Changes with aging of steroidal levels in the cerebrospinal fluid of women.
Topics: Adolescent; Adult; Aged; Aging; Central Nervous System; Dehydroepiandrosterone; Dehydroepiandrostero | 1999 |
Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes.
Topics: Adrenocorticotropic Hormone; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Menopause; Midd | 1999 |
Hormonal reproductive status of women at menopausal transition compared to that observed in a group of midreproductive-aged women.
Topics: Adult; Age Factors; Androgens; Case-Control Studies; Dehydroepiandrosterone; Estradiol; Female; Foll | 2000 |
Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dehydroepia | 1977 |
Oestrogen in breast fluid.
Topics: Adult; Body Fluids; Breast; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; Menopause; M | 1977 |
[Treatment of the climacteric syndrome].
Topics: Adult; Dehydroepiandrosterone; Estradiol; Female; Headache; Hirsutism; Humans; Menopause; Middle Age | 1975 |
Investigation of 17-ketosteriod excretion in mastopathia and premenopausal breast cancer.
Topics: 17-Ketosteroids; Adult; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Etiocholanolone; Fem | 1975 |
Urinary excretion of 17-ketosteroids in patients suffering from mammary cancer.
Topics: 17-Ketosteroids; Aged; Breast Neoplasms; Dehydroepiandrosterone; Etiocholanolone; Female; Humans; Me | 1975 |
Plasma hormone levels in different ethnic populations of women.
Topics: Adrenal Glands; Adult; Africa; Androstenedione; Animals; Asian People; Black People; Breast Neoplasm | 1976 |
Proceedings: Interpretation of data on production and secretion rate measurements of DHEA and DHEAS.
Topics: Breast Neoplasms; Dehydroepiandrosterone; Female; Humans; Menopause; Sulfuric Acid Esters | 1975 |
Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women.
Topics: Adrenal Cortex Hormones; Aged; Androgens; Androstenediols; Androstenedione; Dehydroepiandrosterone; | 1976 |
Polycystic ovarian disease.
Topics: Androstenedione; Clomiphene; Dehydroepiandrosterone; Depression, Chemical; Dexamethasone; Estradiol; | 1976 |
[Treatment of the climacteric symptom complex with a new combined hormone preparation].
Topics: Adult; Aged; Climacteric; Dehydroepiandrosterone; Delayed-Action Preparations; Drug Combinations; En | 1976 |
Plasma dehydroepiandrosterone and androsterone sulphates, androstenedione and urinary androgen metabolites in normal British and Japanese women.
Topics: Adolescent; Adult; Age Factors; Androgens; Androstenedione; Androsterone; Asian People; Dehydroepian | 1976 |
Plasma androstenedione levels in women with breast cancer.
Topics: 17-Ketosteroids; Aged; Androstenedione; Androsterone; Breast Neoplasms; Dehydroepiandrosterone; Fema | 1977 |
Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment.
Topics: Aged; Androgens; Androstenedione; Breast Neoplasms; Castration; Dehydroepiandrosterone; Dexamethason | 1977 |
Effect of prolactin on plasma DHEA (s) levels.
Topics: Adult; Aged; Antidepressive Agents; Dehydroepiandrosterone; Dementia; Depression; Estrogens; Female; | 1977 |
Effect of intravenous calcium load on the serum calcium level in postmenopausal osteoporosis (a study of the pathogenesis, and diagnostic use of the test).
Topics: Calcium; Decanoates; Dehydroepiandrosterone; Female; Humans; Menopause; Nandrolone; Osteoporosis | 1978 |
Dehydroisoandrosterone sulfate in peripheral blood of premenopausal, pregnant and postmenopausal women and men.
Topics: Adult; Age Factors; Circadian Rhythm; Cross Reactions; Dehydroepiandrosterone; Female; Humans; Male; | 1978 |
Steroid hormone metabolism in skin and isolated sebaceous glands: preliminary observations on the effects of age.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Dehydroepiandrosterone; Estradiol; Estrone; Female; Gon | 1979 |
Serum levels of total dehydroepiandrosterone and total estrone in postmenopausal women with special regard to carcinoma of the uterine corpus.
Topics: Aged; Dehydroepiandrosterone; Estrone; Female; Humans; Menopause; Middle Aged; Uterine Neoplasms | 1979 |
Metabolic effects of corticosteroid therapy in post-menopausal women.
Topics: Androstenedione; Bone and Bones; Calcium; Creatinine; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1979 |
Serum testosterone, FSH/LH and urinary excretion of estrogens and corticoids during treatment with an injectable, longacting estrogen-DHEA preparation.
Topics: 17-Ketosteroids; Adult; Castration; Dehydroepiandrosterone; Delayed-Action Preparations; Estradiol; | 1979 |
Metabolism of pregnenolone by human breast cancer. Evidence for 17 alpha-hydroxylase and 17,20-lyase.
Topics: 17-alpha-Hydroxypregnenolone; Aged; Aldehyde-Lyases; Androstenedione; Breast Neoplasms; Cytochrome P | 1979 |
Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Topics: 17-alpha-Hydroxypregnenolone; Aminoglutethimide; Androgens; Androstenedione; Breast Neoplasms; Castr | 1978 |
Effect of exogenous estrogen on serum pregnenolone, cortisol, and androgens in postmenopausal women.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Androgens; Androstenedione; Dehydroepiandrosterone; Dih | 1975 |
Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens.
Topics: 17-Ketosteroids; Aged; Androgens; Androstenedione; Binding, Competitive; Breast Neoplasms; Dehydroep | 1975 |
The hormonal activity of the postmenopausal ovary.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aged; Androstenedione; Castration; Chorionic Gonadotrop | 1976 |
Proceedings: Androgens in human postmenopausal breast cancer.
Topics: Androgens; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Female; Humans; Menopause; | 1975 |
Effect of treatment with estrogen conjugates on endogenous plasma steroids.
Topics: Androstenedione; Dehydroepiandrosterone; Estradiol; Estriol; Estrogens, Conjugated (USP); Estrone; F | 1977 |
Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis.
Topics: Adult; Aged; Dehydroepiandrosterone; Estrogens, Conjugated (USP); Estrone; Female; Humans; Liver Cir | 1979 |
Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bo | 1992 |
Tissue androgens and the endocrine autonomy of breast cancer.
Topics: Adipose Tissue; Androgens; Androstenediols; Androstenedione; Breast Neoplasms; Dehydroepiandrosteron | 1992 |
Endocrine status in stage II vs. advanced premenopausal and postmenopausal breast cancer patients.
Topics: Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Endocrine Glands; Estradiol; Female; Foll | 1992 |
The pituitary-gonadal axis in women with benign or malignant ovarian tumors.
Topics: Aged; Aged, 80 and over; Androstenedione; Chorionic Gonadotropin; Dehydroepiandrosterone; Dehydroepi | 1992 |
Estrogen receptor and C19-5-ene-steroid concentrations in the nuclear fraction from human breast carcinoma tissue.
Topics: Androstenediol; Androstenols; Breast Neoplasms; Carcinoma; Cell Nucleus; Dehydroepiandrosterone; Fem | 1992 |
Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs.
Topics: Aged; Aged, 80 and over; Androstenedione; Arthritis, Rheumatoid; Dehydroepiandrosterone; Dehydroepia | 1992 |
The contribution of body composition, substrates, and hormones to the variability in energy expenditure and substrate utilization in premenopausal women.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; C-Peptide; Calorimetry; Dehydroepiandrosterone; | 1992 |
Endocrine evaluation of patients with benign lumps of the breast.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; E | 1992 |
Low dehydroepiandrosterone circulating levels in premenopausal obese women with very high body mass index.
Topics: Abdomen; Adipose Tissue; Adult; Body Mass Index; C-Peptide; Dehydroepiandrosterone; Female; Glucose | 1991 |
Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; E | 1991 |
The relationship between sex steroids and bone mineral content in women soon after the menopause.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1991 |
Sex hormones in postmenopausal women with primary biliary cirrhosis.
Topics: Aged; Androstenedione; Dehydroepiandrosterone; Dihydrotestosterone; Estradiol; Estrone; Female; Gona | 1991 |
Cigarette smoking and steroid hormones in women.
Topics: Adult; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Humans; | 1991 |
Menopausal age and sex hormones in postmenopausal women with alcoholic and non-alcoholic liver disease.
Topics: Aged; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dihydrotestosterone; | 1991 |
Endocrine status in patients with mammary gland diseases: correlation between steroid hormones and sex steroid binding globulin.
Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1991 |
Gonadotropin secretion during aging in postmenopausal women.
Topics: Aging; Androgens; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estrogens; Female; Follicl | 1991 |
Sex hormone changes in post-menopausal women with primary biliary cirrhosis (PBC) and with cryptogenic chronic liver disease.
Topics: Aged; Androstenedione; Chronic Disease; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estr | 1991 |
Long term effects of a first pregnancy on serum concentrations of dehydroepiandrosterone sulfate and dehydroepiandrosterone.
Topics: Adult; Age Factors; Aged; Body Mass Index; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; F | 1990 |
Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Blood Donors; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandroster | 1990 |
Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20-desmolase enzymatic activity.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aging; Aldehyde-Lyases; Circadian Rhythm; Cortic | 1990 |
Androgens and breast cancer in premenopausal women.
Topics: Adult; Androgens; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1989 |
Persistence of increased bone resorption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late post-menopause.
Topics: Age Factors; Aged; Aged, 80 and over; Bone and Bones; Bone Resorption; Dehydroepiandrosterone; Femal | 1989 |
Sex steroids and bone density in premenopausal and perimenopausal women.
Topics: Adult; Analysis of Variance; Bone and Bones; Cohort Studies; Dehydroepiandrosterone; Dehydroepiandro | 1989 |
Dehydroepiandrosterone sulfate in postmenopausal women: lack of influence of parity.
Topics: Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Humans; Menopause; Middle Aged | 1989 |
Precursors of plasma androstanediol- and androgen-glucuronides in women.
Topics: Adult; Androgens; Androstane-3,17-diol; Androstanols; Androstenedione; Biotransformation; Dehydroepi | 1989 |
The correlation of serum estrogens and androgens with bone density in the late postmenopause.
Topics: Aged; Androgens; Body Height; Body Weight; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrost | 1987 |
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1985 |
Plasma concentrations of sex hormones in postmenopausal women in non-alcoholic cirrhosis.
Topics: Aged; Androstenedione; Dehydroepiandrosterone; Estradiol; Female; Gonadal Steroid Hormones; Humans; | 1985 |
Effects of tamoxifen on testosterone metabolism in postmenopausal women with breast cancer.
Topics: Aged; Breast Neoplasms; Dehydroepiandrosterone; Dihydrotestosterone; Estradiol; Female; Humans; Kine | 1985 |
[Dehydroepiandrosterone enanthate and estradiol valerate for the treatment of menopause].
Topics: Climacteric; Dehydroepiandrosterone; Drug Therapy, Combination; Estradiol; Female; Humans; Menopause | 1986 |
Uptake and concentration of steroid hormones in mammary tissues.
Topics: Adult; Androgens; Androstenediol; Biopsy; Breast; Breast Diseases; Breast Neoplasms; Cell Nucleus; C | 1986 |
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Topics: Adult; Aged; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Drug E | 1986 |
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1986 |
Determination of dehydroepiandrosterone and dehydroepiandrosterone sulphate in blood and tissue. Studies of normal women and women with breast or endometrial cancer.
Topics: Adult; Age Factors; Aged; Body Weight; Breast Neoplasms; Circadian Rhythm; Cross Reactions; Dehydroe | 1987 |
Cations and dehydroepiandrosterone-sulfate in cyst fluid of pre- and menopausal patients with gross cystic disease of the breast. Evidence for the existence of subpopulations of cysts.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Fibrocystic Breast Disease; H | 1986 |
Serum steroid hormone profiles in postmenopausal smokers and nonsmokers.
Topics: 17-alpha-Hydroxyprogesterone; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfat | 1987 |
The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Topics: Androstenedione; Antineoplastic Agents; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandroste | 1987 |
Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass.
Topics: Addison Disease; Adult; Aged; Androgens; Androstenedione; Bone and Bones; Dehydroepiandrosterone; Es | 1987 |
Sustained inhibitory actions of a potent antagonist of gonadotropin-releasing hormone in postmenopausal women.
Topics: Aged; Blood Proteins; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Gonadotropin-R | 1987 |
A prospective long-term study in women from pre-menopause to post-menopause: changing profiles of gonadotrophins, oestrogens and androgens.
Topics: Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Estrone; Female; | 1986 |
Ovarian androgen secretion in patients with galactosemia and premature ovarian failure.
Topics: Adolescent; Adult; Androgens; Androstenedione; Chorionic Gonadotropin; Dehydroepiandrosterone; Dehyd | 1987 |
Shifted distribution of cation-related cyst types in post-menopausal patients with gross cystic disease of the breast.
Topics: Adult; Age Factors; Dehydroepiandrosterone; Female; Fibrocystic Breast Disease; Humans; Menopause; M | 1987 |
Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; H | 1987 |
Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women.
Topics: Aged; Cardiovascular Diseases; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Human | 1987 |
Serum steroid hormone levels in systemic lupus erythematosus (SLE).
Topics: Adolescent; Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Gonada | 1987 |
Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women.
Topics: Aged; Bone and Bones; Calcium; Calcium-Binding Proteins; Dehydroepiandrosterone; Estradiol; Female; | 1987 |
Cigarette smoking and levels of adrenal androgens in postmenopausal women.
Topics: Adrenal Glands; Aged; Androgens; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1988 |
Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone and Bones; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Femal | 1988 |
Epidermal growth factor in breast cyst fluid: relationship with intracystic cation and androgen conjugate content.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Epidermal Growth Factor; Exudates and | 1988 |
The endogenous concentration and subcellular distribution of androgens in normal human premenopausal endometrium, myometrium and vagina.
Topics: Adult; Androgens; Androstenediol; Androstenedione; Cytosol; Dehydroepiandrosterone; Endometrium; Fem | 1988 |
High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androstenedione; Breast Neoplasms; Dehydroepi | 1988 |
Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex.
Topics: Adult; Aged; Aged, 80 and over; Aging; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Femal | 1988 |
The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer.
Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Cortex; Androstenediol; Dehydroepiandrosterone; Endometriu | 1986 |
The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Calcium; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Intestinal Ab | 1985 |
Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue.
Topics: Adolescent; Adult; Age Factors; Aged; Androgens; Androstenediol; Breast; Breast Neoplasms; Cell Nucl | 1985 |
Serum levels of dehydroepiandrosterone sulphate and total estrone in postmenopausal women with special regard to 'non-endocrine' ovarian carcinoma.
Topics: Age Factors; Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estrone; Female; Humans; | 1985 |
Conversion of estrone to estradiol and estradiol to estrone in postmenopausal women.
Topics: Aged; Body Weight; Breast Diseases; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradio | 1985 |
Endocrine profiles and breast cancer.
Topics: 11-Hydroxycorticosteroids; Adult; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol | 1973 |
Basic results of a study of bilateral adrenalectomy for advanced breast cancer. Urinary steroids and related data in 148 patients.
Topics: 17-Ketosteroids; Adrenalectomy; Adult; Androsterone; Body Surface Area; Breast; Breast Neoplasms; Ch | 1973 |
A correlation between urinary steroid metabolites and pathways of steroidogenesis in human breast-tumour tissue.
Topics: 17-Ketosteroids; Adenofibroma; Adrenalectomy; Adult; Aged; Androstanes; Breast Neoplasms; Carcinoma; | 1968 |
Probability of a woman with advanced breast cancer responding to adrenalectomy or hypophysectomy.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenalectomy; Adult; Age Factors; Androsterone; Breast | 1970 |
[Menopause and metabolic disorders].
Topics: Dehydroepiandrosterone; Female; Humans; Menopause; Metabolic Diseases; Middle Aged; Obesity | 1965 |
Enzymatic activities related to steroidogenesis in postmenopausal ovaries of patients with and without endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Carbon Isotopes; Cholesterol; Dehydroepiandrosterone; Endometrium; | 1967 |
[Evaluation of the effect of androgen administration on the maintenance of the individual].
Topics: 17-Ketosteroids; Adrenal Glands; Adrenalectomy; Animals; Body Weight; Bone and Bones; Chromatography | 1968 |
[Study of the dynamics of female urinary 11-deoxy-17-ketosteroid fractions studies by gas-liquid chromatography].
Topics: 17-Ketosteroids; Androsterone; Chromatography, Gas; Dehydroepiandrosterone; Etiocholanolone; Female; | 1968 |
The post-menopausal ovary.
Topics: Androstanes; Dehydroepiandrosterone; Estrogens; Female; Histocytochemistry; Humans; Menopause; Ovary | 1969 |
[Metabolism of dehydroepiandrosterone at the cutaneous level: in vitro experiments].
Topics: Adult; Carbon Isotopes; Culture Techniques; Dehydroepiandrosterone; Female; Fibroma; Humans; Menopau | 1968 |
[Geriatric study on the field of gyneco-obstetrics, with special reference to the significance and application of adrenal androgen in post-menopausal women].
Topics: Adrenal Glands; Aged; Aging; Androgens; Animals; Dehydroepiandrosterone; Female; Humans; Menopause; | 1969 |
[Dehydroepiandrosterone, androsterone and etiocholanolone in plasma and following urine administration of dehydroepiandrosterone sulfate].
Topics: Adult; Androsterone; Dehydroepiandrosterone; Etiocholanolone; Female; Humans; Male; Menopause; Stimu | 1970 |
Serum dehydroepiandrosterone, androsterone and cortisol level in primary postmenopausal and other type osteoporosis.
Topics: Adrenal Cortex Hormones; Androsterone; Dehydroepiandrosterone; Female; Humans; Hydrocortisone; Menop | 1970 |
[Excretion of estrogens and testosterone following administration of dehydroepiandrosterone sulfate].
Topics: Administration, Oral; Adult; Dehydroepiandrosterone; Estradiol; Estriol; Estrogens; Estrone; Female; | 1970 |
Hormonal influences in breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenalectomy; Adult; Age Factors; Androsterone; Animals | 1971 |
[Clinical and experimental studies on the treatment of climacteric disorders with dehydroepiandrosterone sulfate (RO-6 6827)].
Topics: Adult; Blood Cell Count; Blood Coagulation Tests; Climacteric; Dehydroepiandrosterone; Estrogens; Fe | 1970 |
Post-menopausal hyperoestrogenism caused by carcinoma of the adrenal cortex.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Gland Neoplasms; Aged; Carcinoma; Dehydroepiandr | 1970 |
[Therapy of climacteric disorders].
Topics: Climacteric; Dehydroepiandrosterone; Endocrine System Diseases; Estradiol; Female; Humans; Menopause | 1972 |
[Treatment of the menopause syndrome with dehydroepiandrosterone sulfate].
Topics: Administration, Oral; Androstenes; Androsterone; Dehydroepiandrosterone; Endometrium; Estrogens; Eti | 1971 |
Steroid sulphation in vitro by human breast cancer tissue.
Topics: Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Female; Humans; In Vitro Techniques; Menopause; | 1973 |
[Influence of age and menopause duration on the excretion of steroid hormones in precancerous conditions and cancer of the breast].
Topics: Adult; Age Factors; Androsterone; Breast Diseases; Breast Neoplasms; Dehydroepiandrosterone; Etiocho | 1974 |
[Metabolic effects of an estrogen-androgen combination in climateric patients].
Topics: Adult; Blood Coagulation Factors; Dehydroepiandrosterone; Drug Combinations; Drug Evaluation; Endome | 1973 |
Enzyme histochemistry of the menopausal ovary associated with normal and abnormal endometrium.
Topics: Aged; Alcohol Oxidoreductases; Amides; Aminopeptidases; Androgens; Androstenols; Dehydroepiandroster | 1965 |
A technique for the assay of 17-hydroxyprogesterone (17-hydroxy-4-pregnene-3,20-dione) in serum using celite column chromatography and competitive protein binding.
Topics: 17-Ketosteroids; Acetates; Acylation; Alcohols; Androstanes; Anhydrides; Chemical Phenomena; Chemist | 1971 |
Adrenal and testicular contribution to plasma oestrogens.
Topics: 17-Ketosteroids; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Androstanes; Breast Neopl | 1972 |
Effect of ampicillin on the urinary output of steroidal hormones in pregnant and non-pregnant women.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Ampicillin; Androstenes; Corpus Luteum; Dehydroepiandros | 1973 |
Interaction between dehydroepiandrosterone, cyclic adenosine-3',5'-monophosphate and glucose-6-phosphate-dehydrogenase in normal and diseased subjects.
Topics: Adult; Cyclic AMP; Dehydroepiandrosterone; Female; Glucosephosphate Dehydrogenase; Humans; Hyperlipi | 1974 |